

Redox Control of the Cell Cycle in Health and Disease

Ehab H. Sarsour, Maneesh G. Kumar, Leena Chaudhuri, Amanda L. Kalen, and Prabhat C. Goswami

I. Introduction	2985
A. A redox cycle within the cell cycle	2985
B. Reactive oxygen species	2986
C. Antioxidant enzymes and small-molecular-weight antioxidants	2987
D. Redox regulation of cell-cycle progression	2987
E. Redox regulation of cell-cycle proteins	2987
F. RNS signaling and cell-cycle progression	2989
G. Summary	2990
II. Redox Control of the Cell Cycle and Proliferative Disorders	2990
A. Development	2990
B. Aging and cancer	2990
C. Wound healing	2992
D. Fibrosis	2993
1. Radiation-induced fibrosis	2993
2. Lung fibrosis	2993
3. Cardiac fibrosis	2994
4. Liver fibrosis	2994
E. Cardiovascular diseases	2995
F. Diabetes	2997
G. Neurodegenerative diseases	2998
III. Summary and Future Directions	2999

Abstract

The cellular oxidation and reduction (redox) environment is influenced by the production and removal of reactive oxygen species (ROS). In recent years, several reports support the hypothesis that cellular ROS levels could function as “second messengers” regulating numerous cellular processes, including proliferation. Periodic oscillations in the cellular redox environment, a redox cycle, regulate cell-cycle progression from quiescence (G_0) to proliferation (G_1 , S, G_2 , and M) and back to quiescence. A loss in the redox control of the cell cycle could lead to aberrant proliferation, a hallmark of various human pathologies. This review discusses the literature that supports the concept of a redox cycle controlling the mammalian cell cycle, with an emphasis on how this control relates to proliferative disorders including cancer, wound healing, fibrosis, cardiovascular diseases, diabetes, and neurodegenerative diseases. We hypothesize that reestablishing the redox control of the cell cycle by manipulating the cellular redox environment could improve many aspects of the proliferative disorders. *Antioxid. Redox Signal.* 11, 2985–3011.

I. Introduction

A. A redox cycle within the cell cycle

OXIDATION AND REDUCTION (Redox) reactions represent the transfer of electrons from an electron donor (reducing agent) to an electron acceptor (oxidizing agent). The cel-

lular redox environment is a balance between the production of reactive oxygen species (ROS), reactive nitrogen species (RNS), and their removal by antioxidant enzymes and small-molecular-weight antioxidants. The concept of the cellular redox environment regulating the cell cycle dates back to 1931, when Rapkine (255) first demonstrated the oscillating pattern for the accumulation of soluble thiols during mitosis

Reviewing Editors: *Jurgen Bernhagen, Claudia Castro, Peter M. Chumakov, Tohru Fukai, Fuyuki Ishikawa, Hugo Monteiro, Hasan Mukhtar, Mark Smith, Rhian Touyz, and Anonymous*

Free Radical and Radiation Biology Program, Department of Radiation Oncology, University of Iowa, Iowa City, Iowa.

in sea urchin eggs. In 1960, Kawamura *et al.* (146) showed increased protein thiol staining as the mitotic spindle was assembling in sea urchin eggs. The authors found maximal thiol staining in prophase and metaphase, which decreased significantly in anaphase and telophase.

Consistent with these observations, we have reported that the cellular redox environment fluctuates during the cell cycle. HeLa (human adenocarcinoma) cells synchronized by mitotic shake-off were replated and then harvested at different times after plating for flow-cytometry measurements of the cellular redox environment. The fluorescence of a prooxidant-sensitive dye (DCFH₂-DA) was three- to fourfold higher in mitotic cells compared with cells in the G₁ phase. The cellular redox environment increased gradually toward a more-oxidizing environment as G₁ cells moved through the cell cycle (111). These results suggest that a redox control of the cell cycle regulates progression from one cell-cycle phase to the next. This hypothesis is also supported by a recent report demonstrating significantly higher GSH content in the G₂ and M phases compared with G₁; S-phase cells showed an intermediate redox state (64). Furthermore, pharmacologic and genetic manipulations of the cellular redox environment perturb normal cell-cycle progression (200–202, 276, 277).

Overall, these results support the hypothesis that a redox cycle within the cell cycle represents a regulatory link between the oxidative metabolic processes and cell-cycle functions. A defect in this regulation could lead to aberrant proliferation. Aberrant proliferation is central to a variety of human pathologic conditions, such as cancer, wound healing, fibrosis, cardiovascular diseases, diabetes, and neurodegenerative diseases. It is hypothesized that reestablishing the redox control of the cell cycle by manipulating the cellular antioxidant pathways could be an innovative approach to prevent, reverse, or suppress (or a combination of these) many aspects of aberrant cellular proliferation.

Proliferation depends both on cell division and cell death. Cell division drives proliferation, and cell death prevents damaged cells from propagating damaged cellular macromolecules to daughter generations. Reproductive death, apoptosis, and necrosis are the three major modes of cell death. This review article focuses on literature reports demonstrating a redox control of cellular proliferation. The readers are referred to excellent recent reviews discussing the possible role of cellular redox environment and apoptosis in various pathologic conditions (15, 190, 233, 245, 306).

B. Reactive oxygen species

ROS are oxygen-containing molecules that are highly reactive in redox reactions. The partial reduction of molecular oxygen results in the production of superoxide (O₂^{•-}) and hydrogen peroxide (H₂O₂) (120). O₂^{•-} and H₂O₂ react with transition metal ions (*e.g.*, cuprous and ferrous ions) through Fenton and Haber–Weiss chemistry, generating the highly reactive hydroxyl radical (HO[•]) (121).

ROS are primarily produced intracellularly by two metabolic sources: the mitochondrial electron-transport chain and oxygen-metabolizing enzymatic reactions such as xanthine oxidases, the cytochrome P450 system, NADPH oxidases, myeloperoxidase, and nitric oxide synthase (27, 30, 151, 189, 278, 284, 355). ROS levels also are dependent on oxygen concentrations. Most eukaryotic organisms require oxygen to

survive. Oxygen is the terminal electron acceptor during energy production. It accepts an additional electron to create superoxide, a more reactive form of oxygen. Superoxide can be converted to hydrogen peroxide (H₂O₂) spontaneously.

ROS were traditionally thought of as toxic byproducts of living in an aerobic environment because they are known to damage cellular macromolecules (Fig. 1), which could subsequently lead to cell death (296). However, in recent years, several studies have shown that ROS can function as signaling molecules that regulate numerous cellular processes, including proliferation (9, 13, 19, 38, 39, 200–202, 262, 276, 277, 315).

The second-messenger properties of ROS are believed to activate signaling pathways by activating tyrosine kinases, tyrosine phosphatases, MAP kinases, or ion channels (235). Furthermore, interactions between specific receptor-ligands also are known to generate ROS (76). This dual function of ROS, as signaling molecules or toxins, could result from the differences in their concentrations, pulse duration, and sub-cellular localization. The concentration-dependent effects of ROS regulating different cellular processes are clearly evident in a recent report by Laurent *et al.* (165). NIH 3T3 fibroblasts treated with 0.02–0.13 μM H₂O₂ enhanced proliferation, whereas treatment with 0.25–2 μM H₂O₂ resulted in cell death. Prostate cancer DU-145 cells treated with low concentrations of H₂O₂ (100 nM to 1 μM) enhanced c-Fos expression, which was associated with an increase in cell proliferation, whereas a higher concentration of H₂O₂ (200 μM) decreased c-Fos expression and induced cell-cycle arrest (341). Therefore, although higher levels of ROS can be toxic, low levels of




FIG. 1. ROS signaling and cellular processes. Reactive oxygen species (ROS; *e.g.*, O₂^{•-} and H₂O₂) are produced intracellularly by the mitochondrial electron-transport chain and flavin-containing enzymes. Superoxide dismutase (MnSOD and CuZnSOD) converts O₂^{•-} to H₂O₂; catalase (CAT), peroxidase (Prx), and glutathione (GSH)-glutathione peroxidase (GPx) neutralize H₂O₂ to water. H₂O₂ in the presence of metals can generate hydroxyl radical (HO[•]); HO[•] damages cellular macromolecules. ROS can serve as second messengers influencing multiple signaling pathways that regulate proliferation, quiescence, differentiation, and cell death. The redox potentials related to these cellular processes were adapted from literature report (282).

ROS may serve as signaling molecules regulating numerous cellular processes, including proliferation (Fig. 1).

C. Antioxidant enzymes and small-molecular-weight antioxidants

Cellular ROS levels are maintained both by the production of ROS and by their neutralization by antioxidant enzymes and small-molecular-weight antioxidants. In addition to spontaneous conversion, superoxide is converted to hydrogen peroxide by superoxide dismutase enzymes (MnSOD, CuZnSOD, and EcSOD). Catalase (CAT) and glutathione peroxidase (GPx) neutralize H₂O₂ to water (Fig. 1). MnSOD, a nuclear-encoded and mitochondria-localized homotetrameric enzyme, is the primary defense against mitochondrially generated ROS (196). CuZnSOD is in both the cytoplasm and the nucleus. EcSOD is present in the plasma membrane and extracellular space (98). CAT is found primarily in the peroxisomes, and different isozymes of GPx are found in most subcellular compartments (225, 350).

Hydroperoxides also are neutralized by thioredoxin/thioredoxin reductase, glutaredoxin/glutaredoxin reductase, and the six-member family of peroxiredoxins (93, 262). Peroxiredoxins (Prxs) are a family of peroxidases that reduce H₂O₂ and alkyl hydroperoxides to water and alcohol. Prxs include both the 2-cys (Prx I-IV) and 1-cys (Prx V and VI) family of oxidoreductase proteins: Prx I, II, and VI are present in the cytosol; Prx III and V (short and long forms) are localized in the mitochondrion; and Prx IV is present in the endoplasmic reticulum and extracellular space (261). Thioredoxin is a small, 12-kDa ubiquitous protein. It reduces protein disulfides and itself is oxidized during this redox reaction. Oxidized thioredoxin is reduced by thioredoxin reductase, a seleno-cysteine protein, in the presence of NADPH (218). Glutaredoxins (Grx) are a GSH-dependent oxidoreductase family of 1-Cys and 2-Cys proteins of low molecular mass, 9–14 kDa. The human Grx family includes three members: Grx1 is present in the cytosol and nucleus, and Grx2 and Grx5 are present in mitochondria. Grx catalyzes the formation and reduction of the protein-mixed-disulfide forms in presence of the GSH/GSSG-redox couple and NADPH (130). Additional intracellular small-molecular-weight antioxidants include cysteine, vitamin C (ascorbic acid), and vitamin E (α -tocopherol) (77). Therefore, changes in the antioxidant enzyme activities or small-molecular-weight antioxidant levels or both could perturb the cellular redox environment, which in turn could affect the redox regulation of the cell-cycle progression.

D. Redox regulation of cell-cycle progression

The mammalian cell cycle has five distinct phases; quiescence is G₀, whereas the proliferative state encompasses the G₁, S, G₂, and M phases. In response to mitogenic stimuli, quiescent cells enter the proliferative cycle and may transit back to the quiescent state. Reentry into quiescence is essential to prevent aberrant proliferation as well as to protect the cellular life span. The quiescent state is frequently incorrectly referred to as cellular senescence or differentiated states. Unlike differentiation and cellular senescence, quiescence is a reversible process that protects the proliferative capacity of cells essential for cell and tissue renewal. One of the best examples of the quiescent state *in vivo* is stem cells that retain the capacity to proliferate.

As mentioned previously, the redox regulation of cell-cycle progression was first reported in the cell cycle of sea urchin

eggs (255). In mammalian cells, a transient increase in cellular prooxidant levels in G₁ is required for entry into S phase (202). Inhibition of this prooxidant event with an antioxidant like N-acetyl-L-cysteine (NAC) inhibited progression from G₁ to S. NAC-induced inhibition of entry into S phase was associated with an increase in MnSOD activity and a decrease in cyclin D1 protein levels (201). MnSOD activity has been shown to regulate a mitochondrial "ROS-switch," in which a superoxide signal promotes proliferation, and a hydrogen peroxide signal supports quiescence (277). The concept of the cellular redox environment regulating cell-cycle progression is further supported by recent observations of SOD activity influencing the oxidative stress-induced activation of the G₂-checkpoint pathway in human oral squamous cancer, pancreatic cancer, and glioma cells (97, 105, 143).

Furthermore, in cultured hamster fibroblasts, sublethal doses of ROS added exogenously stimulated proliferation (39–41). Likewise, H₂O₂ in nanomolar concentrations generated from growth factor receptor–ligand binding is known to facilitate cell proliferation (37). NADPH oxidases, such as Nox1 and Nox4, are required for growth factor-mediated production of H₂O₂, which subsequently activates multiple signaling pathways including the SOS-RAS-Raf-Erk and PI3K/AKT pathways (69, 259, 260). NADPH oxidase is a multi-subunit membrane-bound oxidase composed of p22^{phox}, p47^{phox}, p40^{phox}, p67^{phox}, and Nox2 (or any of its homologues: Nox1, Nox2, Nox3, etc.). The enzyme consists of two membrane-spanning subunits: p22^{phox}, which serves as a stabilizing and regulatory subunit for the superoxide-producing subunit Nox (174). The cytoplasmic components include p47^{phox}, p67^{phox}, p40^{phox}, and Rac, which helps to regulate the assembly of the functional oxidase and its activity (263). NADPH oxidase is found in various cell types, including neutrophils, smooth muscle cells, endothelial cardiac myocytes, and vascular and cardiac fibroblasts. Manipulations of cellular redox environment, by using NAC, inhibited proliferation in mouse embryonic fibroblasts, hepatic stellate cells, and vascular smooth muscle cells (147, 160, 202). The redox potential in proliferating cells is reported to be –240 mV, and necrotic cells exhibit the highest oxidizing state (–150 mV); the redox potential for the quiescent cells is in between proliferation and differentiation states, whereas apoptotic cells exhibit a redox potential of –170 mV (Fig. 1) (134, 282).

The hypothesis of a redox cycle regulating the cell cycle is also evident in other organisms (59, 328). The yeast metabolic cycle (YMC) in budding yeast oscillates between glycolytic and respiratory metabolism. Yeast cell-division cycle is restricted to the reductive phase of the YMC when oxygen consumption is minimal. The level of NADPH that provides a reducing equivalent to numerous enzymes peaks during the reductive phase of the YMC. Furthermore, the YMC in budding yeast coordinates with periods of gene expression regulating essential cellular and metabolic events (328). Mutations in the metabolic genes and cell-cycle checkpoint genes disrupt the communication between the YMC and cell-cycle progression (59). The literature discussed earlier overwhelmingly supports the hypothesis that a redox cycle within the cell cycle regulates progression through different cell-cycle phases.

E. Redox regulation of cell-cycle proteins

Progression through the cell-cycle phases is orchestrated by sequential and periodic activation of positive regulators,

cyclins, and cyclin-dependent kinases (CDKs) (Fig. 2). Progression from G_0/G_1 to S is largely regulated by the D-type cyclins (cyclin D1 and D2) in association with CDK4-6 (112, 299, 300). CDK4-6 kinase activity in early G_1 is low primarily because of lower levels of cyclin D1. After mitogenic stimulation, cyclin D1 peaks in mid-to-late G_1 , coinciding with higher levels of CDK4-6 kinase activity. Cyclin D1 expression is regulated at the transcriptional, posttranscriptional, translational, and posttranslational levels. A recent report indicates that cyclin D1 is transcriptionally downregulated by forkhead box O (FoxO3a) transcription factor, which subsequently inhibits cell-cycle progression (283). The FoxO-family of transcription factors are known to be phosphorylated by the mitogenic-signaling pathway, phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT). Phosphorylated FoxO is excluded from the nucleus, thereby relieving FoxO-mediated gene repression (33). NAD-dependent deacetylases, sirtuin 1 and 2, also are known to activate FoxO transcription factor activity (35, 339).

The cyclin D1/CDK4-6 kinase complex partially phosphorylates the retinoblastoma (Rb) protein, causing a conformational change that releases the E2F family of transcription factors (Fig. 2). Cyclin E/CDK2 kinase is activated in late G_1 to early S and facilitates further Rb phosphorylation (112, 299). E2F activates the expression of multiple S-phase-specific genes that are required for DNA replication and progression through the S phase (214). The G_1 phase of the cell cycle is critical in deciding whether proliferation will be arrested or continued. Temin (318) first proposed the presence of a "decision point" in the G_1 phase beyond which cells become committed to progress through the cell cycle and divide. In 1974 Pardee (236) renamed the decision point as "restriction point" and defined it as the time in G_1 after which a cell is committed to enter the S phase, more or less independent of external conditions. Although the mechanisms regulating the "restriction point" are not completely understood, it was observed that a change in the cellular redox environment toward a more-oxidizing environment is required for entry into S phase (202). Thus, the "restriction point" could represent a redox threshold necessary for progression from G_0/G_1 to S.

The cyclin A/CDK2 kinase complex regulates progression through S and G_2 phases. The cyclin B1/CDK1 kinase complex, along with CDC25C phosphatase, regulates progression from G_2 to M phase. Earlier it was believed that the functions of

individual cyclins and CDKs are specific to a specific cell-cycle phase. However, recent reports demonstrate redundancy in these cell-cycle-regulatory protein functions. For example, cell-cycle progression is unaffected in CDK2, CDK4, and CDK6 knockout mouse embryos, suggesting that CDK1 can substitute for other CDKs. Cyclin D1 knockout mice are viable, possibly because of redundancy from cyclin E function. However, knockout of cyclin A and cyclin B are lethal in mice (5, 128). Cyclins are the positive regulators of cell-cycle progression, and cyclin-dependent kinase inhibitors (CKIs) are the negative regulators. The INK family of CKIs (INK4B, p15; INK4A, p16; INK4C, p18; INK4D, p19) specifically inhibit cyclin D/CDK4-6 kinase complexes. The KIP family of CKIs (p27 and p57) inhibits mainly cyclin E/CDK2 kinase complexes. The inhibitory effect of p21 is ubiquitous, and it can inhibit all cyclin/CDK kinase activities. p21 and p27 also are known to facilitate the assembly of cyclin/CDK complexes (60, 161).

Redox regulation of cell-cycle proteins p21, Rb, cyclin D1/CDK4-6 kinase, and CDC25 phosphatase is observed in NAC-treated mouse and human fibroblasts (37, 175, 279, 288, 340, 351). NAC treatments shift the cellular redox environment toward a more-reducing environment. This change is associated with a decrease in cyclin D1, an increase in p27, and Rb hypophosphorylation (199, 201, 202). The decrease in cyclin D1 is inversely correlated with MnSOD activity (201). Considering that MnSOD is mitochondrial and cyclin D1 is a nuclear protein, this inverse correlation is intriguing. One possible mechanism of this interorganelle crosstalk could be due to the FoxO-mediated transcriptional control of cyclin D1 and MnSOD expression. FoxO3a is known to activate MnSOD transcription, while inhibiting cyclin D1 transcription (153, 283). FoxO3a-mediated induction in MnSOD transcription is associated with the quiescence state. During the quiescence state, FoxO3a has been shown transcriptionally to upregulate p27 expression (198). Inhibition of FoxO3a activity is anticipated to relieve cyclin D1 from transcriptional repression, which in turn is anticipated to support cellular proliferation.

Alternatively, the redox sensitivity in cyclin D1 expression could also be regulated by posttranslational mechanisms. NIH3T3 mouse fibroblasts carrying the Thr286A cyclin D1 mutation suppressed NAC-induced cyclin D1 degradation. This suggests that redox-sensitive phosphorylation of Thr286 could influence cyclin D1 protein levels (201). Furthermore, the redox sensitivity in cyclin D1 accumulation could also be




FIG. 2. A redox cycle within the cell cycle that is preserved in the daughter generations. The cell cycle has two distinct growth states: quiescence (G_0) and proliferation (G_1 , S, G_2 , and M). Progression through the cell cycle is regulated by cell-cycle phase-specific activation of cyclins and cyclin-dependent kinases (CDKs). In the G_1 phase, cyclin D1/CDK4-6 and cyclin E/CDK2 are the major regulators. Cyclin A/CDK2 and cyclin B/CDK1 regulate the S, G_2 , and M phases. Cyclin/CDK complexes phosphorylate retinoblastoma (Rb) protein, which undergoes conformational change, releasing the transcription factor, E2F. E2F regulates transcription of S phase-specific genes. The periodicity in the cellular redox environment is represented by the line graph.

regulated by the thiol-redox reactions of critical cysteine residues. Consistent with this hypothesis, mutations of specific cysteines were found significantly to decrease cyclin D1 protein levels compared with wild-type cyclin D1 (unpublished observations).

In contrast to the effect of NAC on cyclin D1, H_2O_2 inhibits cyclin D1 protein degradation in Her14 fibroblasts, resulting in cyclin D1 accumulation (188). Overall, this literature supports the hypothesis that redox regulation of the cell cycle could be mediated *via* the redox-sensitive regulation of the cell-cycle-regulatory protein function.

The significance of the relation between cyclin D1 expression and the cellular redox environment is clearly evident from a recent report by Sakamaki *et al.* (274). Physiologic levels of cyclin D1 decreased aerobic glycolysis and mitochondria size and function *in vivo*. Mitochondria activity was enhanced by genetic deletion of cyclin D1. Subsequent study by Wang *et al.* (338) showed that cyclin D1/CDK4-6 phosphorylates nuclear respiratory factor 1 (NRF1) at Ser47, suppressing its transcriptional activation of nuclear-encoded mitochondrial gene expression (338). Likewise, dephosphorylation of NRF1 in the absence of cyclin D1 promotes expression of nuclear-encoded mitochondrial genes. These results provide strong evidence for cyclin D1 coordinating cellular metabolism and cell-cycle progression.

Another cell-cycle-regulatory protein that exhibits redox sensitivity in its function is CDC25 phosphatase. CDC25 phosphatases are a family of dual specific phosphatases that dephosphorylate pThr14 and pTyr15 on CDKs and activate the cyclin-CDK kinase activity (287). Dunphy and Kumagai (84) showed *in vitro* that the phosphatase activity of CDC25 can be inhibited by using *N*-ethylmaleimide, a thiol-alkylating agent, or mutating a single conserved cysteine residue. Recently, Savitsky and Finkel (279) showed that the H_2O_2 treatment of HeLa cells induces an intramolecular disulfide bond between two critical site cysteines, Cys377 and Cys330, of CDC25 (Fig. 3). This thiol-disulfide redox reaction is associated with an inhibition in CDC25 phosphatase activity. CDC25 harboring the double mutant of the cysteines was resistant to the H_2O_2 -induced inhibition in its phosphatase activity. These observations are consistent with earlier reports suggesting that ROS could reversibly modify the redox state of specific cysteine residues in phosphatases (protein tyrosine phosphatases and dual-specificity phosphatases), inactivating their activities, which could favor Ser/Thr phosphorylation-dependent signal pathways initiating proliferation (95, 205, 260, 314, 320).

Hydrogen peroxide could influence the redox state of protein thiols, two-electron reactions (36) (Fig. 4). The reduced form of cysteine in protein (RSH) can be oxidized to sulfenic acid (RSOH), which can be further oxidized to sulfinic (RSO₂H) and sulfonic (RSO₃H) acids. The sulfinic and sulfonic forms of proteins are believed to be targeted for degradation; the sulfenic form can react with another RSH to form the disulfide, RSSR. RSSR can be then reduced back to RSH by cellular antioxidant machinery. This thiol-disulfide exchange reaction can regulate many of the cell-cycle-regulatory protein functions during the redox regulation of the cell cycle. In addition, superoxide can initiate one-electron reactions that can alter the redox state of metal cofactors (*e.g.*, Fe and Zn) (Fig. 4) present in many kinases and phosphatases, thereby affecting their activities. Thus, both one- and two-electron




FIG. 3. Thiol-redox reactions regulating CDC25 phosphatase activity. The reduced form of cysteine in proteins can undergo oxidation reactions to form sulfenic, sulfinic, and sulfonic acids. Sulfinic and sulfonic forms are believed to be irreversible, whereas the sulfenic form can conjugate with other reduced thiols (RSH) to form a disulfide bridge. Cellular antioxidant systems can reduce the disulfide bond and generate the reduced form of the cysteine in proteins. Mutational analysis identified cysteine 330 and 377 of CDC25 phosphatase as the sites for thiol redox reactions; the reduced (-SH) form of CDC25 has phosphatase activity, whereas the oxidized (-S-S-) form is inactive.

reactions can participate in the redox regulation of cell-cycle proteins during progression from one cell-cycle phase to the next.

F. RNS signaling and cell-cycle progression

Reactive nitrogen species (RNS) are molecules derived primarily from the reactions of nitric oxide. Nitric oxide (NO) is a short-lived and highly reactive diffusible free radical that is known to regulate various biologic processes. NO is produced from L-arginine by the enzymatic action of nitric oxide synthase (NOS) (70). The NOS family of proteins includes the constitutive (cNOS), inducible (iNOS), neuronal (nNOS), and endothelial NOS (eNOS). Inflammation and oxidative stress induce iNOS expression. NO in the central and peripheral nervous system is believed to regulate cell-cell communication. eNOS generates NO in the blood vessels to regulate vascular functions. NO reacts with $O_2^{\bullet-}$ to form peroxynitrite. Peroxynitrite is highly reactive and can damage proteins by nitration. Nitration of structural proteins, like actin and neurofilaments, is known to disrupt filament assembly, leading to various pathologic disorders like atherosclerosis, ischemia, and septic lung, among others (17, 167).




FIG. 4. ROS regulate protein activity. Superoxide dismutase (SOD) converts superoxide ($O_2^{\bullet-}$) to hydrogen peroxide (H_2O_2). $O_2^{\bullet-}$ can modulate the activities of kinases and phosphatases by interacting with metals in one-electron reactions. H_2O_2 can regulate protein function by manipulating thiol-redox reactions in two-electron reactions (36).

NO can also mediate important biologic effects *via* the activation of specific cell-signaling pathways. Lower concentrations of NO are known to activate NF- κ B transcription factor, possibly by S-nitrosation of p21 and activation of I κ B. In contrast, higher concentrations of NO inhibit the DNA-binding activity of the SP-1 transcription factor (79, 167). Higher levels of NO have been shown to accelerate S-phase entry basally, and facilitate entry into mitosis apically in developing chick neuroepithelium (227). Low-molecular-weight S-nitrosothiol, S-nitroso-N-acetylpenicillamine promotes the nitrosation of p21 Ras and the activation of the Ras-ERK 1/2-MAP kinase signaling pathway. This activation in the ERK-signaling pathway leads to cell-cycle progression in rabbit aortic endothelial cells (17). NO inhibits proliferation in vascular smooth muscle cells, resulting in G₁ delay. NO-induced G₁ delay is accompanied with a decrease in cyclin A/CDK2 activity and an increase in p21 protein levels (324). Results from these studies indicate that the cell-type specificity and signaling pathway(s) could significantly influence the mitogenic and cytostatic properties of NO.

G. Summary

This literature clearly supports the hypothesis that periodic oscillations in metabolic redox reactions, a redox cycle, within the cell cycle represent a fundamental mechanism linking oxidative metabolic processes to the cell-cycle-regulatory processes. The periodicity in cellular redox environment is maintained by a delicate balance between the production of ROS, RNS, and their removal by nonenzymatic and enzymatic antioxidants. Redox regulation of the cell-cycle-regulatory proteins could be influenced by the presence of redox-sensitive motifs, such as cysteine residues or metal cofactors in kinases and phosphatases. The literature presented in the next section integrates information supporting the concept that perturbations in the redox control of the cell cycle could lead to proliferative disorders. It is hypothesized that reestablishing the redox cycle by manipulating the cellular antioxidant pathways could reverse, suppress, and/or prevent many aspects of proliferative disorders.

II. Redox Control of the Cell Cycle and Proliferative Disorders

A. Development

Development in living organisms involves two distinctive criteria: proliferation and differentiation. Cells proliferate in low oxygen concentrations throughout the embryonic stage and in higher oxygen concentrations during neonatal life. This environmental transition from low to high oxygen during development creates a gradient of ROS that may have direct and indirect effects on cellular proliferation. ROS signaling is known to regulate many of the transcription factors that influence development (*e.g.*, NF- κ B, AP-1, and HIF-1) (162).

The role of antioxidants during development is well documented. For example, homozygous MnSOD-knockout mice survive the embryonic stage of development. However, these mice die after birth of lactic acidemia, cardiomyopathy, and degeneration of the basal ganglia (138, 325, 326). Developmental defects in MnSOD-knockout mice are associated with damage to mitochondrial aconitase, complex I, and succinate dehydrogenase. In comparison to control mice,

defects in MnSOD-knockout mice were very pronounced after oxygen exposure, with a subsequent increase in ROS production (166, 171). MnSOD overexpression is known to promote differentiation (62, 168, 310).

CuZnSOD-knockout mice are viable (194), but slowly develop neuronal axonopathy, which is not as pronounced at birth in comparison to mice lacking MnSOD (166, 171). Another example of SOD-dependent developmental defects relates to CuZnSOD overexpression in Down syndrome patients; aberrant placental formation is common in these patients (10, 99, 100). Furthermore, a lack of selenium-containing protein antioxidants, such as thioredoxin reductase and phospholipid hydroperoxide glutathione peroxidase (GPx-4), is lethal in early gestation (191, 353). Interestingly, another selenium-containing protein, antioxidant selenoprotein W, was found to be highly expressed in proliferating cells during the development of the heart, skeletal muscle, and the nervous system in mice. However, as cells exit from the cell cycle, the expression of this protein is decreased (140, 177).

The changes in the cellular redox environment during development could affect both proliferation and differentiation. Although proliferation is the major event in development, both positive (cyclin/CDK) and negative (CKI) regulators of the cell cycle are involved. Results from knockout mice demonstrated that a lack of individual cyclins and CDKs is not lethal to the organism (63, 89, 184, 231, 249, 303, 304), with the exception of cyclin B1 and cyclin A2, which are fatal in early gestation (28, 208, 209). In general, these mice have a normal developmental life, suggesting that redundancy in cyclin and CDK functions could compensate for the absence of an individual member of the cyclin and CDK family of proteins. It also is interesting to note that whereas individual cyclin (or CDK)-knockout embryos develop normally to adults, they are susceptible to proliferative disorders later in life. An additional complication of this regulation is that these impaired proliferative activities are tissue specific. Cyclin-dependent kinase inhibitor (INK4 and CIP/KIP) homozygous knockout mice showed viable embryos and normal neonatal development. However, these animals did develop an increase in tumor incidence later in life (75, 150, 155, 164, 295). p57-Knockout mice were found to be neonatal fatal with severe developmental defects in the gastrointestinal tract and abnormal cell proliferation in placenta, cartilage, and eye lenses (352, 356).

This literature suggests that the cellular redox environment and cell-cycle-regulatory proteins might collectively regulate development. Although individual cell cycle-regulatory proteins may not affect the development process because of redundancy, their presence as a family is essential for the normal developmental process.

B. Aging and cancer

One of the most well-stated definitions of aging was offered by Caleb Finch (94), who defines aging as "a nondescript colloquialism that can mean any change over time, whether during development, young adult life, or senescence. Aging changes may be good (acquisition of wisdom); of no consequence to vitality or mortality risk (male pattern baldness); or adverse (arteriosclerosis)." The numerous theories of aging can be broadly classified into two major categories: error and program theories. According to the program theory, aging

occurs because of a preexisting external or internal program. The program theory of aging includes both the "Hayflick limit" and the telomere-shortening phenomenon. The error theory considers aging to be a cumulative damage process (289). The free radical theory of aging, originally proposed by Harman (123), is an example of the error theory of aging. ROS-mediated damage to critical cellular macromolecules is believed to accumulate as a function of age and to lead to deleterious effects associated with degenerative diseases of aging, senescence, and carcinogenesis (96). A recent study clearly demonstrated that mitochondria-targeted overexpression of human catalase extends the median and maximal life span of mice by 20% (285). Mitochondrial overexpression of catalase delayed age-associated loss in mitochondrial DNA deletions, cardiac pathology, and cataracts in mice (285). Previous studies reported that overexpression of MnSOD and CuZnSOD extended *Drosophila* life span (230).

In 1961, Hayflick (reviewed in ref. 49) showed that human diploid fibroblasts cultured *in vitro* divide a finite number of times (Hayflick limit) before irreversible growth arrest, also known as senescence. Cellular senescence is associated with specific changes in cell morphology that include increased cell volume, expression of neutral senescence-associated β -galactosidase activity, and increased production of extracellular matrix degradative enzymes such as collagenase and stromelysin. Cellular senescence is believed to be caused by telomere shortening. Telomeres are repetitive DNA sequences (TTAGGG in vertebrates) present at the ends of chromosomes and are essential for maintaining chromosomal integrity. During DNA replication, 50–200 bp of telomeric DNA are not replicated at the end of the S phase of the cell cycle. Because telomerase, the enzyme that synthesizes telomeric DNA *de novo*, is not expressed by most human cells, telomeres shorten with each cell cycle. When the telomeres shorten from the maximum size of 10–15 kb to an average size of 4–6 kb, human cells irreversibly arrest in growth, producing a characteristic phenotype, defined as senescence (48, 308). These observations are known now as the telomere hypothesis of the Hayflick limit.

It is important to mention that a majority of cell-culture experiments are performed at nonphysiologic oxygen concentrations of 21% compared with physiologic concentrations of 4%. Because ROS are byproducts of oxygen metabolism, it is anticipated that oxygen concentrations will significantly affect cellular ROS levels: 21% oxygen environment is known to reduce population doublings (PDs) in cultured cells (294, 348, 349). Furthermore, human and mouse fibroblasts cultured at 21% oxygen concentrations exhibit significantly reduced replicative life span despite mouse cells having long telomeres (43, 237). Consistent with these previous reports, our unpublished results show that normal quiescent human skin fibroblasts cultured at 4% *vs.* 21% oxygen concentrations protect these cells from age-related loss in proliferative capacity. Interestingly, the protection of proliferative capacity at 4% *vs.* 21% oxygen environment correlated with the preservation of mitochondrial morphology. These results suggest that oxygen concentrations could significantly influence the redox biology of the cell cycle.

Results from several studies suggest that the redox regulation of the cell cycle could be influenced by the redox-controlled maintenance of telomeres. Overexpression of EcSOD in human fibroblasts decreased the intracellular peroxide content, slowed the telomere shortening rate, and

elongated the life span of these cells under normoxia and hyperoxia (293). Minamino *et al.* (203) showed that hypoxia extends the life span of vascular smooth muscle cells through activation of telomerase activity. Furthermore, ectopic expression of telomerase increased MnSOD expression by more than sevenfold (298). Telomerase-immortalized cells have higher levels of the p21 cell-cycle-regulatory protein (49, 83, 110, 334). Thus, the redox regulation of the cell cycle could protect replicative senescence *via* a redox-sensitive regulation of the telomeres and telomerase activity.

Redox regulation of the cell cycle could also influence the chronologic life span of aging. Chronologic life span is characterized as the capacity of quiescent (G_0) cells to reenter the proliferative cycle (124). The mechanisms regulating the chronologic life span are poorly understood. In response to mitogenic stimuli, quiescent cells enter the proliferative cycle and subsequently transit back to the quiescent state. This reversible property of cellular quiescence is highly essential to protect the chronologic life span and avoid aberrant proliferation. MnSOD activity protects the chronologic life span of normal human skin fibroblasts from age-dependent loss (276). Quiescent normal human skin fibroblasts cultured for 40 to 60 days were unable to reenter the proliferative cycle after replating. This inhibition of reentry was associated with a significant accumulation of p16 and a decrease in p21 cyclin-dependent kinase inhibitor protein levels. Interestingly, MnSOD overexpression suppressed age-associated increase in p16 accumulation, maintained p21 at a higher level, and restored the ability of quiescent fibroblasts to reenter the proliferative cycle (Fig. 5). Furthermore, MnSOD activity has been shown to regulate a ROS switch favoring a superoxide signal regulating the proliferative cycle and a hydrogen peroxide signal supporting quiescent growth. Higher levels of MnSOD activity were associated with quiescence, whereas lower levels support proliferation. MnSOD activity-regulated transitions between quiescent and proliferative growth was associated with changes in cyclin D1 and cyclin B1 protein levels (277). These results support the hypothesis that MnSOD activity could maintain a redox-balance protecting the chronologic life span.

Cellular ROS levels and the protection of proliferative capacity are also apparent in hematopoietic stem cells (322). FoxO transcription factor-deficient hematopoietic stem cells (HSCs) showed reduced ability to repopulate (321). Because FoxO is known to regulate antioxidant enzyme (MnSOD and catalase) and cell-cycle (cyclin D1 and p27) genes transcription (154), it has been suggested that ROS could mediate the proliferative capacity of HSCs. Consistent with this notion, small-molecular-weight antioxidant (NAC) treatment of FoxO-deficient HSCs protected the proliferative capacity of HSCs (322). Overall, this literature supports the hypothesis that a loss in the redox control of the cell cycle during transitions between quiescent (G_0) and proliferative (G_1 , S, G_2 and M) cycles could severely affect the proliferative capacity of cells.

Cancer is a disease manifesting late in life, suggesting that the very biology of aging contributes to its exponential increase in the older population. Cancer risk is elevated with aging, which could be due to an increase in ROS production or decrease in ROS removal or both (157, 331). Carcinogenesis can be divided into three distinct stages: initiation, promotion, and progression. Initiation can occur because of mutations in one or more genes, which result in loss or gain of function.




FIG. 5. MnSOD activity protects the chronologic life span of normal human skin fibroblasts. Quiescent normal human skin fibroblasts cultured for 40–60 days at 21% oxygen environment lose their capacity to reenter the proliferative cycle after replating of cells at a lower density. This loss in proliferative capacity is associated with an increase in cellular ROS levels and p16 accumulation. Overexpression of MnSOD suppressed p16 accumulation, increased p21 levels, and protected quiescent fibroblast proliferative capacity (276).

Promotion is the functional enhancement and alteration of the pathway induced by initiation. Progression is the continuing change of the unstable karyotype, often leading to aberrant proliferation. Aberrant proliferation in cancer cells could be due to a loss in the redox regulation of the cell cycle. Oberley and Buettner (224) were first to report that cancer cells exhibit lower levels of antioxidant enzyme activities compared with their respective normal cells, in particular MnSOD. Other studies suggest that oxidative stress could significantly contribute to cancer progression, possibly by perturbing the redox control of the cell cycle (103, 118, 129, 239, 240, 292). Redox potential in normal cells correlates with Rb phosphorylation status during the cell cycle, suggesting that perturbations in cellular redox potential could significantly affect the function of a tumor-suppressor gene (129). Furthermore, it is hypothesized that the metabolic redox-signaling pathways could initiate as well as promote carcinogenesis (108). This hypothesis is based on numerous studies demonstrating a regulatory role of MnSOD activity in cancer cell growth in both cell-culture and tumor xenograft animal model systems (62, 223, 346, 347, 357). These results suggest that reestablishing the redox control of the cell cycle by manipulating the expression of ROS-removal enzymes (*e.g.*, MnSOD) could suppress or inhibit (or both) carcinogenesis.

Recent reports enlighten an additional aspect of carcinogenesis that relates to the tumor microenvironment. Several studies report that aged normal human breast and prostate fibroblasts support epithelial malignancies (11, 16, 50, 81, 157, 228, 271). The majority of human cancers are carcinomas originating from epithelial cells. Fibroblasts are the primary component of the stroma that supports these epithelial tissues. Campisi *et al.* (47, 50, 51) showed that senescent human fibroblasts enhanced cellular proliferation in premalignant and malignant epithelial cells *in vitro*, and tumor growth and metastasis in mice *in vivo*. Prostate epithelial cells from tissue with aged stroma can become tumorigenic when co-cultured with tumor-burden fibroblasts (228). Likewise, exposure of

mammary gland stroma to irradiation or carcinogens stimulates nonmalignant epithelial cell proliferation and promotes tumor formation (11). Although the mechanisms regulating this phenomenon are not completely understood, the secreted growth factors, cytokines, and extracellular matrix proteins from aged fibroblasts are believed to enhance premalignant and malignant epithelial cell proliferation. Because many of the growth factors and cytokines are known to generate ROS, it is hypothesized that ROS signaling derived from aged fibroblasts could provide mitogenic stimuli to premalignant and malignant epithelial cells.

C. Wound healing

Wounds are an inevitable part of life. They could arise both from internal and external injuries. Wound healing is a complex process that can be grouped into three major overlapping stages: inflammation, proliferation, and maturation or closure (Fig. 6). ROS are involved in all three stages of wound healing (31, 226, 256, 270, 302, 311). The inflammation stage of the wound-healing process is one of the most widely studied areas for ROS production, and it is the stage during which most ROS are produced (270). The production of ROS during the inflammation stage is believed to protect cells from pathogens and regulate angiogenesis (290). Hydrogen peroxide levels are higher in the early stages of wound repair compared with late stages; superoxide is also detected in the leading edge of the wound area (270). MnSOD, CuZnSOD, catalase, and glutathione peroxidase levels increases during the normal wound-healing process (311). Likewise, treatment with SODs and administration by hydrogels containing CuZnSOD or transgenic expression of MnSOD resulted in better wound healing in mouse models (56, 61, 291). In contrast, lower levels of antioxidants (*e.g.*, glutathione) were associated with improper wound healing (207, 256).




FIG. 6. Redox control of the cell cycle during wound healing. The wound-healing process can be divided into three stages: inflammation, proliferation, and closure. Higher ROS levels are essential during the inflammatory stage of the wound-healing process to defend against pathogens. Lower levels of ROS later in the wound-healing process could be mitogenic, facilitating quiescent cell entry into the proliferation cycle. Redox control of quiescent cell entry into and exit from the proliferative cycle could be essential to prevent aberrant proliferation and improper closure.

Although inflammation is the initial stage, the wound-healing process is mainly dependent on the proliferative stage. Cells repopulate during the proliferative phase and prepare the wound for closure and healing. The repopulation process depends on the ability of quiescent cells to reenter and subsequently exit the proliferative cycle (Fig. 6). Quiescent normal human skin fibroblast entry into and exit from the proliferative cycle is dependent on cellular superoxide and hydrogen peroxide levels regulated by MnSOD (277). Redox-sensitive regulation of cyclin D1 and cyclin B1 protein expression correlated with the quiescent fibroblast entry into and exit from the proliferative cycle (277). Cyclin E and Ki-67 protein levels are known to increase during the early stages of the wound-healing process (359). Increased levels of cyclin D1/CDK4-6 correlate with better wound closure (332). Furthermore, ROS are also known to regulate cellular migration and proliferation during different physiologic responses (217, 252). The decrease in cyclin levels at later stages of the wound-healing process was associated with an increase in p21 and p27 (12, 359, 360, 364). p21 and p27 were upregulated in the migrating epithelial cells on the leading edge of the wound, whereas the basal cells showed an increase in cyclin A and Ki-67 protein levels (12). Redox-sensitive control of the proliferative stage of wound healing is critical for normal wound healing.

Loss of the redox-sensitive control in the inflammatory or proliferative stages, including migration and reentry into the proliferative cycle, could lead to higher accumulations of collagen, elastin, fibronectin, and proteoglycan that are hallmarks of keloids and hypertrophic scars (1, 44, 178). These results support the hypothesis that tight redox control of the cell cycle is necessary for proper wound healing.

D. Fibrosis

Fibrosis is defined as the formation of fibrous tissue as a reaction or repair process due to disease, treatment, or exposure to chemicals. Fibrosis involves the overgrowth, hardening, and often scarring of tissue due to excess collagen. Fibrosis is most common in the lung, heart, peritoneum, and liver.

1. Radiation-induced fibrosis. Radiation-induced fibrosis (RIF) is a serious and common complication of radiation therapy that causes chronic pain, neuropathy, swelling of lymph nodes, and limited motion in the joints. It occurs most commonly in the head, neck, breast, and connective tissues. Risk factors for developing RIF include high-dose radiation, large tissue volume exposed to radiation, and radiation combined with surgery or chemotherapy.

The biologic effects of ionizing radiation begin with the generation of both early and late ROS accumulation (105). ROS signaling could activate quiescent fibroblasts to differentiate into myofibroblasts, which have the phenotype of smooth muscle cells. Myofibroblasts appear during the initial inflammatory phase, and they are present during the constitutive fibrotic phase. Myofibroblasts are characterized by increased proliferation and reduced production of extracellular matrix metalloproteinases (187). The persistent excess of myofibroblasts is believed to be responsible for the areas of hypercellular fibrosis and the clinical observation of radiation-induced fibrous swellings (74). Numerous biochemical compounds, such as cysteine, pentoxifylline, and

tocopherol, are used to minimize radiation-induced damage to normal tissue (74).

EcSOD-overexpressing mice exhibit decreased fibrosis, which correlated with a decrease in TGF- β and Smad3 protein levels (144, 243). Likewise, liposomal delivery of CuZnSOD in a 3D-culture of myofibroblasts decreased TGF- β levels and facilitated myofibroblast reversal to normal fibroblasts (335). Although in general, the effect of TGF- β is growth inhibition, TGF- β is also known to promote proliferation of fibroblasts. TGF- β has been shown to decrease p21 and p27 protein levels in WI38 human lung fibroblasts and NIH3T3 mouse fibroblasts, respectively (80, 257). This decrease in cyclin-dependent kinase inhibitors was accompanied by a significant increase in cyclin E/CDK2 kinase activity. A decrease in cyclin D2 expression in fibroblasts isolated from breast cancer patients correlated with a low risk for the development of RIF (264). TGF- β remains elevated long after the radiation treatment (6). The increase in TGF- β can result in prolonged inhibition of p21 and p27, which could support continued proliferation facilitating the development of RIF.

2. Lung fibrosis. The most common types of lung fibrosis include idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and bleomycin-, asbestos-, or cigarette smoke-induced fibrosis (137, 148). The lung is subject to the highest exposure to oxygen, which makes it susceptible to ROS- and RNS-induced abnormalities. In addition to the ETC and NADPH oxidases, ROS in lung can be generated by myeloperoxidase, eosinophil peroxidase, and xanthine oxidase (149). Xenobiotics or pathologic conditions can overcome the detoxification enzyme system (104, 149, 246, 337). GSH levels were found to be low in the epithelial lining fluid of IPF patients (52). In bleomycin-induced lung fibrosis, increased oxidation of cysteine (Cys) to its oxidized form, cystine (CySS), and a decrease in the GSH pool were observed (137). IPF patients also exhaled more NO as compared with healthy individuals (265). Failure to cope with the oxidant insult could be the major factor causing fibrosis. This hypothesis is supported by a recent report of aerosolized administration of NAC attenuating bleomycin-induced lung fibrosis (117).

The oxidant insult could lead to a loss of regulation of the fibroblast cell cycle, causing the resulting fibrosis. Fibroblasts derived from areas of fibrosis proliferate faster than cells derived from histologically normal areas of lung tissue (141). Patients with IPF have elevated levels of nitric oxide, which could stimulate proliferation of human lung fibroblasts, possibly *via* NF- κ B-mediated activation of cyclin D1 expression and progression from G₀/G₁ to S phase (127, 186, 265). NO-induced proliferation in a normal human fetal lung fibroblast cell line, MRC-5, is associated with inhibition of p21 and p27, activation of cyclin/CDK complexes (cyclin D1/CDK4-6 and cyclin E/CDK2), and hyperphosphorylation of Rb (Fig. 7) (57).

As in RIF, oxidants and TGF- β may interact to enhance fibrosis in patients with IPF (149). Active TGF- β has been detected in patients with pulmonary fibrosis, in contrast to healthy individuals in whom TGF- β is present mostly in the latent form (23). TGF- β has been shown to activate NADPH oxidase in human fibroblasts, which is associated with an increase in ROS levels (319). TGF- β -induced increase in ROS levels inhibits cell proliferation by inducing a G₁ arrest, decreases cyclin D1/CDK4-6 kinase activities, and increases p21,




FIG. 7. Redox control of the cell cycle and lung fibrosis. Elevated levels of nitric oxide (NO) can stimulate proliferation of lung fibroblast by the NF- κ B-mediated activation of cyclin D1 expression. NO also is known to decrease p21 and p27 cyclin-dependent kinase inhibitors, which is associated with an increase in cyclin D1/CDK4-6 and cyclin E/CDK2 kinase activities, as well as Rb hyperphosphorylation. Hyperphosphorylated Rb undergoes conformational change releasing the E2F transcription factor. Activation of the E2F-targeted S-phase-specific gene expression prepares cells for DNA synthesis and subsequent cell division.

p27, and p16 protein levels (71, 206, 323). Consistent with these results, p21 overexpression demonstrates an antiapoptotic and antifibrotic effect in attenuating bleomycin-induced pulmonary fibrosis in mice (135). It is unclear how TGF- β could promote proliferation in RIF and inhibit proliferation in pulmonary fibrosis.

3. Cardiac fibrosis. Cardiac fibrosis refers to the thickening of heart valves due to increased proliferation of cardiac fibroblasts and subsequent collagen accumulation. The perturbation in cardiac fibroblast proliferation is believed to be regulated by ROS signaling generated from the membrane-bound NADPH oxidase, a major source of superoxide in the heart. An increase in Nox2, also known as gp91^{phox}, has been observed in the perivascular space and at sites of fibrosis in both the right and left ventricles (358). Cardiovascular NOX is thought to release low levels of superoxide intracellularly. These lower amounts of ROS could serve as second messengers initiating cellular signaling pathways that control many cellular processes, including proliferation.


Both the renin-angiotensin system and TGF- β play important roles in the development of cardiac fibrosis. Angiotensin II (Ang II) is an effector hormone of the circulating renin-angiotensin system, which has endocrine functions in maintaining cardiovascular homeostasis. Ang II-dependent induction of TGF- β expression induces cardiac fibroblast proliferation and phenotypic conversion to myofibroblasts (266). Ang II increase in cell proliferation is associated with a significant increase in cyclin D and cyclin A expression in neonatal rat cardiac myocytes (272). Furthermore, Ang II-induced phosphorylation of Rb on serine 480, a mitosis-specific event, suggests that Ang II promotes cell division (272). Overexpression of p21 and p16 inhibited Ang II-induced cardiac myocyte hypertrophy (220). These results support the hypothesis that a loss in the redox regulation of the cell cycle could contribute to the genesis of cardiac fibrosis (Fig. 8).

4. Liver fibrosis. The adult human liver is the largest internal organ, and it plays an important role in the metabolism and the clearance of body toxins. The parenchymal cells of the

liver contain most of the hepatic antioxidant enzymes, but Kupffer cells, hepatic stellate cells (HSCs), and endothelial cells are more exposed and sensitive to oxidative stress. Chronic liver injury is associated with accumulation of matrix proteins, causing fibrosis (336). After liver injury, parenchymal cells regenerate and try to replace necrotic or apoptotic cells. This is usually accompanied by an inflammatory response and the deposition of extracellular matrix (ECM). The excess accumulation of extracellular matrix in hepatic fibrosis is regulated mostly by HSCs. After liver injury, HSCs undergo "activation" that is accompanied with the transition from quiescent to proliferative growth (101). In the healthy liver, the HSCs are in a quiescent state and function to store vitamin A. In response to liver damage, quiescent HSCs lose vitamin A and differentiate into a myofibroblast phenotype expressing α -smooth muscle actin (101). This phenomenon is a hallmark of cellular response to liver injury. MnSOD activity is known to regulate transitions between quiescent and proliferative growth states (277), suggesting that quiescent HSC entry into the proliferative cycle could be regulated by the cellular redox environment.

The cellular redox environment in hepatocytes and Kupffer cells may be regulated by ROS produced from the NADP/NADPH oxidase system or leakage of electrons from the ETC (or both), followed by univalent reduction of oxygen to superoxide anion (72, 172). Substrates like ethanol, polyunsaturated fatty acids, and iron may enhance ROS production. Noncytotoxic levels of superoxide in human HSCs have been shown to enhance procollagen type I expression through the antioxidant-sensitive pathway Ras/ERK, which stimulates HSC migration and the profibrogenic response (219). ROS signaling could be influenced by the activities of various antioxidant enzymes, the expression of which is regulated by a number of redox-sensitive transcription factors, including NF- κ B and NRF1. Quiescent HSCs lack NF- κ B in contrast to activated HSCs, suggesting that a redox-sensitive activation of NF- κ B could regulate expression of NF- κ B-targeted genes providing an appropriate cellular redox threshold for quiescent HSC entry into the proliferative cycle (Fig. 9). Consistent with this hypothesis, inhibition in NF- κ B activity by using

FIG. 8. Redox control of the cell cycle and cardiac fibrosis. ROS generated from membrane-bound NADPH oxidase may activate antioxidant enzyme expression that could influence the cellular redox environment in favor of cyclin D and A expression, supporting proliferation. Angiotensin II (Ang II) can induce cardiac fibroblast proliferation and its phenotypic conversion to myofibroblasts, leading to excess collagen and extracellular matrix deposition.



pyrrolidine dithiocarbamate is known to protect rats from the development of hepatic fibrosis (34). Inhibition in NRF1 could alter the expression of antioxidant response element (ARE)-responsive antioxidant enzymes that could perturb the cellular redox environment and subsequently affect proliferation, cell death, and increased collagen synthesis in HSCs that collectively results in liver fibrosis (195).

E. Cardiovascular diseases

Redox signaling has been implicated in the pathogenesis of all major diseases, including those of the cardiovascular system. Cardiovascular disease is the number one cause of death in the United States, accounting for ~35.3% of all deaths in 2005 (2). Oxidative stress in cardiovascular biology was once considered only in terms of injury, damage, and dysfunction. However, an accumulating body of literature suggests that low to moderate concentrations of ROS may act as secondary messengers and signaling molecules regulating redox-sensitive processes during the vascular smooth muscle cell (VSMC) and cardiac myocyte cell-cycle progression.

Coronary heart disease is caused by atherosclerosis, the narrowing of vessels due to a buildup of plaque, which may lead to chest pains and heart attack. VSMCs are known to play an important role in the formation of fibrous plaques in atherosclerosis and initial thickening after angioplasty (267, 286). Focal accumulations of monoclonal VSMCs are precursors to atherosclerotic lesions (286). In these accumulations, VSMCs cause vessel-wall inflammation, lipoprotein retention, and fibrous cap formation that stabilizes plaques. Proliferation of VSMCs in atherosclerosis has been linked to inflammation, apoptosis, and matrix alterations (85). Additionally, VSMC proliferation has been identified as the primary mechanism of pathogenesis in restenosis, transplant vasculopathy, and vein bypass graft failure (29). Hypertension and diabetes are also associated with VSMCs growth (235).

In general, an injury to vessels initiates vascular proliferative disorders. This injury can cause endothelial denudation/dysfunction, inflammation, and VSMC activation and proliferation (85). ROS generated during VSMC proliferation could originate from the NADPH oxidase or growth factors or both. Nox4 is highly expressed in vascular wall cells, and Nox2 is predominantly expressed in VSMCs (179). Treatment of VSMCs with Nox1 antisense inhibits superoxide production and ROS-dependent signaling pathways (163). ROS generated from growth factors, such as platelet-derived growth factor (PDGF), are associated with increases in smooth muscle cell proliferation (248). Increased expression of PDGF and its receptors has been found in lesions of atherosclerosis (248). Overexpression




FIG. 9. Redox control of the cell cycle and liver fibrosis. ROS signaling can recruit quiescent hepatic stellate cells to the proliferative cycle by upregulating the activity of redox-sensitive transcription factors, NF-κB and NRF1. Proliferating hepatic stellate cells can subsequently differentiate into myofibroblasts.

of catalase inhibited VSMC proliferation, indicating a causal link between ROS signaling and cell proliferation in VSMCs (315). Furthermore, TGF- β , angiotensin II, epidermal growth factor, insulin-like growth factor, and basic fibroblast growth factor could also initiate medial proliferation of VSMCs (86, 114, 173, 183, 210). Angiotensin II-induced VSMC proliferation is regulated at least in part *via* the NADPH oxidase-dependent generation of H₂O₂-sensitive signaling pathways (115).

Extracellular signal-regulated kinases (ERKs) of the mitogen-activated protein kinase (MAPKs) family form one of the H₂O₂-sensitive signaling pathways that could contribute to VSMC proliferation (235). Exogenous addition of H₂O₂ induced VSMC proliferation *via* tyrosine phosphorylation of MAPKs (8, 253, 254, 315). ERK 1/2 activation is known to increase cyclin D1 (4, 102). PDGF can increase PIP₃ levels, which in turn mediate p70S6K and AKT activation. AKT is known to phosphorylate GSK-3 β and thus negatively affect its kinase activity. Inactivation of GSK-3 β kinase activity inhibits cyclin D1 Thr286 phosphorylation, thereby stabilizing cyclin D1. An increase in cyclin D1 facilitates cells progression from G₁ to S phase (68). AKT-mediated inactivation of GSK-3 β and stabilization of cyclin D1 have been proposed recently for enhanced proliferation of VSMCs after treatment with betacellulin and amphiregulin (Fig. 10) (301).

Furthermore, PDGF is known to activate redox factor 1 (Ref-1) by altering its redox status, enhance AP-1 activity, and increase cell-cycle-regulatory protein expression, facilitating progression from G₀/G₁ to S phase in VSMCs (125). CDK2, cyclin E, cyclin A, and PCNA protein levels were low in uninjured rat carotid arteries. However, a significant increase in these protein levels occurs within 2 days of balloon angioplasty. This increase in cell-cycle-regulatory proteins was present even after 10 days after injury, suggesting a continuous activation of proliferation during this period (169). Abundant expression of cell-cycle proteins has been observed in regions of human restenotic lesions, which also showed increased VSMCs proliferation (345). Disruptions of the E2F-Rb complex and inhibition of p53 have also been shown to stimulate proliferation of VSMCs (22).

Hydrogen peroxide is known to increase c-myc and c-fos mRNA levels, which can influence cell-cycle progression (253). Studies have shown the proliferative effects of c-myc in VSMCs (21, 213). Diez *et al.* (78) demonstrated an association between enhanced expression of c-myc and increased expression of cyclin A in VSMCs. c-Fos, conversely, promotes AP-1 transcription factor activity, which could activate cyclin A expression *via* binding to the AP1-consensus promoter sequence (317). Figure 10 summarizes the possible pathways of the redox control of cellular proliferation leading to the development of atherosclerosis.

In contrast to ROS activating VSMC proliferation, nitric oxide (NO) is a potent mitogenic repressor. NO suppresses the promoter activity for cyclin A gene transcription, resulting in decreased cyclin A mRNA and protein levels, which was associated with cell-cycle arrest (116). Additionally, NO-induced inhibition of CDK2 activity is associated with Rb hypophosphorylation, increased p21 expression, and inhibition in cell-cycle progression from G₁ to S (136).

As atherosclerosis progresses and vessels are continually narrowed, myocardial infarction is a likely result. Cardiac myocytes rapidly proliferate during fetal life, but are terminally differentiated soon after birth. This limits the ability of

the heart to restore function after injury. However, recent evidence suggests that cardiac myocytes may retain some proliferative potential (20, 142, 176). Additionally, cardiac progenitor cells have been identified that give rise to cardiac myocyte-like cells (3). Ki-67, a common indicator of proliferation, was found to be positive in 4% of myocytes near infarction sites and in 1% in distant myocytes in human tissue sections. Mitotic spindles, contractile rings, karyokinesis, and cytokinesis were also identified in these tissue sections (20). These results suggest that cardiac myocytes could be recruited to the proliferative cycle, at least under ischemia/reperfusion conditions.

Cardiac tissue contains many of the same growth factors seen in VSMCs, such as basic fibroblast growth factor and insulin-like growth factor (145). ROS are known to be generated in the ischemic myocardium, especially after reperfusion during acute myocardial infarction (131). Superoxide derived HO[•] and R[•] from reperfusion (366) may account for up to 50% of the final size of the myocardial infarction (354). The major sources of ROS in ischemic reperfused myocardium are from mitochondria, xanthine oxidase, and phagocyte NADPH oxidase (82, 281, 344). Although high levels of these ROS can cause significant damage, lower levels of ROS could stimulate myocyte proliferation for repair. H₂O₂, added to ventricular myocytes, activated the ERK pathway, leading to myocytes proliferation (159). Myocardial infarction is associated with enhanced expression of cyclin E, cyclin A, cyclin B, CDK2, and CDK1 in the remaining viable ventricular cardiac myocytes (258). In both acute and end-stage heart failure, the levels of p21, p27, and p57 reverted to a pattern similar to that observed in human fetal heart; p21 and p27 declined, whereas p57 expression was significantly increased (42). Although it appears that some ROS may activate proliferation, nitric oxide may have a different effect.

Recent evidence showed NO protects the myocardium from ischemia/reperfusion injury, possibly by scavenging superoxide (40). NO-induced increase in p21 and inhibition of cyclin A/CDK2 activity prevented apoptosis in reperfused cardiomyocytes (181).

This literature supports the hypothesis that the cellular redox environment could influence VSMCs and cardiac myocytes proliferation in cardiovascular diseases. Interestingly, one of the recent strategies to improve cardiac function has been aimed at increasing the number of viable cardiac myocytes by manipulating cell-cycle-regulatory protein expression (307). The application of antioxidants could be a viable redox-based therapy for preserving the redox control of the cell cycle in VSMCs and cardiomyocytes. Additionally, some drugs already in use may have previously unknown redox function. Statins have been used to lower cholesterol to prevent heart disease by inhibiting 3-hydroxyl-3-methylglutaryl-CoA reductase and increasing LDL. Recently they have been shown also to have an antioxidant effect (313). Statins inhibit isoprenylation, resulting in decreased translocation of Rac-1 to the membrane; Rac1 is required for NADPH oxidase activity (180, 342, 343). Statins also decreased mRNA expression of NADPH oxidase subunits (343). In addition to preventing oxidant production, statins have been shown to increase catalase in liver and aortic vascular smooth muscle cells (139, 343). These effects also may serve to reduce the oxidant burden to mitogenic levels to allow repair in vasculature.




FIG. 10. Redox control of the cell cycle and cardiovascular diseases. Receptor-mediated ROS signaling can activate cellular proliferation during atherosclerosis. ROS generated from PDGF–ligand interaction can convert PTEN from the reduced form (phosphatase active) to the disulfide form (phosphatase inactive). Inactive PTEN can favor AKT phosphorylation, which in turn can phosphorylate GSK-3 β , thereby stabilizing cyclin D1 and facilitating proliferation. ROS signaling can also initiate the ERK pathway, activating growth-promoting transcription factors, c-fos and c-myc. c-fos and c-myc can transcriptionally activate cyclin D1 and cyclin A expression, supporting proliferation. Nitric oxide inhibits proliferation by suppressing cyclin A expression and increasing p21 protein levels.

F. Diabetes

Diabetes is one of the earliest recorded diseases, found in the documents of ancient Greek and Hindu cultures (250, 268). Diabetes affects almost 8% of the United States population, and it was the seventh leading cause of death in 2006 (54). Type I, or insulin-dependent, diabetes mellitus, is usually diagnosed early in life and consists of 5–10% of the general diabetes diagnoses. Type I diabetes is denoted by a defect in insulin production and is most successfully treated with glucose monitoring and insulin administration. Type II, or non-insulin-dependent diabetes mellitus, is usually diagnosed later in life and is associated with obesity. Type II diabetes represents 90–95% of all diabetes diagnoses. Type II diabetes can be controlled with diet, medication, and glucose monitoring. Some common complications of diabetes are heart disease, stroke, high blood pressure, blindness, kidney disease, nervous system disease, delayed wound healing, amputation, and dental disease (54).

Although the exact cause of diabetes is not completely understood, one hypothesis is that the cellular redox environment and control of the cell cycle could significantly contribute to the development of this disease. A recent study by Houstis *et al.* (133), in an experimental model of insulin re-

sistance, suggests that increased ROS activate insulin resistance in TNF- α and glucocorticoid dexamethasone-treated 3T3-L1 adipocytes. This resistance can be suppressed by prior treatments with small-molecular-weight antioxidants, N-acetyl cysteine (NAC), and manganese (III) tetrakis (4-benzoic acid) porphyrin (MnTBAP) (133). The authors showed that 3T3-L1 adipocytes overexpressing CuZnSOD, MnSOD, and cytoplasmic and mitochondrial-targeted catalase were able to prevent insulin resistance in this experimental model system of diabetes. Furthermore, results from gene-expression analysis showed six of the ROS-biology-related genes (metallothionein, cytochrome P450, xanthine dehydrogenase, haptoglobin, and ceruloplasmin) increased by two- to sevenfold. Interestingly, these results also showed approximately a two- to fivefold decrease in the G₀/G₁ switch gene that is believed to regulate quiescent cell transition into the proliferative cycle (133). Hydrogen peroxide treatment of muscle cells (L6), human embryonic kidney fibroblasts, and mouse fibroblasts conferred insulin resistance (24, 122). Results from several studies showed that the increase in ROS levels precedes the hyperglycemia and insulin resistance, suggesting a causal role of ROS in the disease process (24, 122, 133).

Hyperinsulinemia also has been linked to diabetes as a cause for insulin resistance demonstrated *in vivo* and *in vitro*

(73, 297). Several different types of cells, including adipose, insulin-sensitive hepatoma, and human skin fibroblasts, have shown evidence of ROS generation after insulin stimulation (55, 182). Prolonged insulin treatment of 3T3-L1 adipocytes inhibited insulin signaling and glucose uptake, while producing ROS (106). The reader is referred to two of the recent reviews discussing a possible link between insulin/IGF-1 and ROS/RNS signaling pathways (14, 234).

The cellular redox environment also is suggested to have a role in the late complications of diabetes, such as atherosclerosis, β -cell dysfunction, and nephropathy. Similarly, evidence of a preceding antioxidant imbalance has been linked to abnormal glucose levels (25, 275). Perturbation in the cellular redox environment also is known to alter free fatty acid levels (FFAs). FFA produced during the process of lipolysis has been shown to be higher in obese and diabetic individuals (26). Elevated FFA levels are known to uncouple oxidative phosphorylation, generate ROS, and reduce glutathione levels (88). Glucose autooxidation, NADPH oxidase, NOS, and superoxide generated from mitochondrial complexes I, II, and III are believed to be some of the sources of ROS production that could contribute to the development of hyperglycemia (13, 170, 216, 330, 365). Intermittent and stable hyperglycemia has been shown to cause ROS and eventually impaired cellular functions in pancreatic β cells (132, 242).

β -Cell dysfunction in the pancreas is one of the earliest events in the progression of type II diabetes (330). A majority of diabetes research focuses on the differentiation, function, and maintenance of pancreatic β -cell mass. In type II diabetes, the β cells exhibit defective proliferation and growth, whereas in type I diabetes, β cells are depleted by an autoimmune reaction (250). A further distinction of β cells is their low levels of antioxidant enzymes and thus their subsequent sensitivity to ROS and the eventual damage to cellular macromolecules (113). β Cells have a short cell-cycle duration compared with other cells in the body, but not all β cells retain the ability to reenter the cell cycle (316). The low percentage of proliferating β cells has been linked to lower CDK1 serine/threonine kinase and cyclin B1 mRNA levels (185). Some other cell-cycle proteins linked to diabetes are p27, CDK4, cyclin D1, and cyclin D2 (158). p27-Knockout mice showed increased β -cell proliferation and suppressed hyperglycemia, whereas p27 overexpression resulted in severe diabetes (329). CDK4-knockout mice showed poor β -cell proliferation and insulin-deficient diabetes (249). INK4a (p16) inhibits CDK4, which is necessary for β -cell proliferation (327). Transgenic overexpression of p16 exhibits decreased pancreatic islet proliferation (156). Mice expressing a mutant form of CDK4 that is unable to bind p16 develop pancreatic hyperplasia (249). Human and rat pancreatic β cells overexpressing CDK4 and cyclin D1 *via* adenovirus-mediated gene delivery enhanced Rb phosphorylation and increased proliferation by approximately two- to 10-fold (66). Cyclin D2-knockout mice develop severe diabetes by 12 weeks, because of defective β -cell replication, and these β cells also are unable to increase cyclin D1 or D3 expression until 2 weeks after birth (107). A cyclin D2-knockout mouse cross-bred with a heterozygote cyclin D1 mouse ablated β -cell proliferation, suggesting that cyclin D1 could also contribute to β -cell proliferation in these mice (158). AKT has been shown to regulate β -cell proliferation by cyclin D1, cyclin D2, and p21, through increased CDK4 activity (91). These results provide compelling evidence in support of the hy-

pothesis that perturbations in the redox control of cell-cycle proteins could significantly affect β -cell proliferation and the development of diabetes.

G. Neurodegenerative diseases

Neurodegeneration is a pathologic condition affecting the nerves of the brain and spinal cord. Neuronal cell death occurs over the course of many years. In addition, distinct populations of neurons are targeted in different diseases; in Alzheimer's disease, 40% of the superior temporal sulcus is lost over a 10-year period, whereas 45% of the caudal substantia nigra is lost in Parkinson's disease within the same period of time (92, 109, 221). Throughout development, neuronal precursors proliferate to make more neurons than necessary. Apoptosis removes this excess, and the remaining neurons are terminally differentiated (152).


Alzheimer's disease is the most common form of dementia (87). The hallmark histopathology for this disease includes senile plaques, which are β -amyloid aggregates, and neurofibrillary tangles, which are tau protein aggregates. β -Amyloid, when bound to copper or iron, has been implicated as a major source of oxidative stress in Alzheimer's disease (18, 269, 280). Nunomura *et al.* (222) demonstrated that oxidative stress is highest early in Alzheimer's disease and lower later in the disease process. Transgenic mice overexpressing β -amyloid precursors, presenilin1 and amyloid precursor protein, showed an induction of oxidative stress (192). Presenilin 1 also has been shown to inhibit phosphorylation of Rb, suggesting a possible correlation between the cell cycle and oxidative stress in Alzheimer's disease (241). Activated microglia, upregulated in Alzheimer's disease, and surrounding tangles and plaques can be additional sources of NO and $O_2^{\bullet-}$ (53, 119, 193).

Parkinson's disease is characterized by rigidity, resting tremors, and bradykinesia (65, 90). This disease is caused by selective degeneration of neuromelanin-containing neurons, resulting in a significant decrease in the neurotransmitter dopamine in the substantia nigra. Affected cells histologically contain Lewy bodies and cytoplasmic inclusions of α -synuclein protein.

Amiotrophic lateral sclerosis (ALS) is another progressive neurodegenerative disease that has a direct link to ROS. Mutations in CuZnSOD account for $\sim 20\%$ of all familial cases of ALS (273, 305). More than 100 known mutations are found in CuZnSOD, all of which are dominant, and most of which confer a toxic gain of function (244, 305).

Whereas higher levels of ROS ($O_2^{\bullet-}$ and H_2O_2) could result in oxidative stress and neuronal cell death, lower levels of ROS could be mitogenic. Rb hyperphosphorylation, increased levels of cyclin D, and E2F-1 redistribution to the cytoplasm have been observed in motor neurons and glia of ALS patients (251). CDK4 is highly abundant in mice overexpressing CuZnSOD mutants (215). Neurofibrillary tangles, present in many neurodegenerative diseases, may be an ideal source for mitogenic levels of H_2O_2 . MAPK p38 expression has been localized to these tangles, providing a link between oxidative stress and cell-cycle reentry (7, 152, 362). Consistent with this hypothesis, cells treated with dopamine, a drug known to have an oxidative metabolism with the ability to generate ROS (152), activated a neuronal expression of cyclin B1 and CDK5 (303). Treatment of these cells with antioxidants blunted the activation of the cell-cycle protein expression, sug-

FIG. 11. Redox control of the cell cycle and neurodegenerative diseases. ROS signaling can activate growth-promoting signaling pathways facilitating unscheduled entry into the cell cycle. An aborted cell cycle can lead to neuronal cell loss, which is a hallmark of neurodegenerative diseases.



gesting that the ROS signaling could trigger a mitogenic response in neuronal cells.

Many classic markers of proliferating cells, such as cyclin D1, CDK4, and Ki67, have been detected in degenerating neurons (197, 211, 212, 247, 309, 361). The presence of cyclin E and CDK2 in degenerating neurons suggests that the mitogenic properties of ROS facilitate neuronal cell progression from G₀ to the G₁/S border (212). The identification of cyclin B1, CDK1, and tau proteins as well as binucleated cells in neuronal tissues of patients diagnosed with neurodegenerative diseases suggest that terminally differentiated neuronal cells could be susceptible to unscheduled entry into the proliferative cycle (333, 361, 363). However, the absence of mitotic structures in these neurons suggests that the ROS levels that facilitate neuronal cell unscheduled entry into the cell cycle might not be high enough to stimulate neuronal cell entry into mitosis (152). This premise is consistent with a previous report demonstrating a gradual increase in cellular ROS levels as cells progress through the cell cycle; cells in M phase exhibit the highest oxidative state (111). The literature discussed earlier supports the hypothesis that the absence of an appropriate redox control of the neuronal cell cycle after reentry could activate the cell-death pathways, resulting in neuronal cell loss and the subsequent pathology of various neurodegenerative diseases (Fig. 11).

III. Summary and Future Directions


Not too long ago, ROS, diverse and abundant in biologic systems, were thought of as toxic byproducts of living in an aerobic environment. ROS are known to cause damage to cellular macromolecules, including both nuclear and mitochondrial genomes, proteins, and lipids, resulting in apoptosis or necrosis. However, recent evidence suggests ROS could be beneficial and necessary for many of the cellular processes, including proliferation and growth arrest. The literature dis-

cussed in this review indicates that a periodic oscillation in metabolic redox reactions represents a fundamental mechanism linking oxidative metabolic processes to the cell-cycle-regulatory processes. The periodicity in intracellular redox state can be regulated by a delicate balance between production of ROS and subsequent removal by nonenzymatic and enzymatic antioxidants. It is important to note that specific species of ROS can be a determining factor that drives cellular proliferation and ultimately cellular responses in health and disease. An “ROS switch” exists in which superoxide signaling promotes proliferation, and hydrogen peroxide signaling supports quiescence (277).

Future studies are necessary to decipher how the same ROS could regulate necessary biologic processes but also be toxic to cells. It is possible that this dual function of ROS could be due to the difference in their concentrations (threshold), pulse duration (flux), subcellular localization, and cell types. We believe that advances in the quantitative redox biology research may resolve many of these intriguing questions in the very near future.

Another future direction would be to determine whether the activation of the redox-sensitive signaling pathways is specific to a particular source of ROS generation. Must all cellular processes be under the control of specific ROS-sensitive signaling pathways? Can the redox regulation of the cell cycle be controlled by direct modifications of redox-sensitive motifs (cysteine residues, metal cofactors) present in cyclins/CDKs, CKIs, and phosphatases? It has been reported that critical thiol-disulfide exchange reactions between specific cysteine residues significantly affect CDC25 phosphatase activity (279). Our unpublished observations showed that specific cysteines in cyclin D1 could regulate its protein levels. These results suggest that many of the redox-sensitive processes regulating cell-cycle progression could be directly regulated by thiol-redox reactions in specific cell-cycle-regulatory proteins.

FIG. 12. Redox control of the cell cycle in human health and disease. A schematic illustration of cell-cycle regulatory processes and redox-gradient is presented. A loss in the redox control of the cell cycle can lead to aberrant proliferation, which is a hallmark of various proliferative disorders. It is hypothesized that reestablishing the redox control of the cell cycle may alleviate many aspects of proliferative disorders.



As demonstrated, ROS appear to play a critical role in many human diseases, especially in relation to the cell-cycle control (Fig. 12). However, it is interesting to note that many clinical trials using antioxidants to treat or prevent cancer (126, 229), coronary disease (32), and other diseases have been inconclusive or have yielded negative results. These results reemphasize the complexity of the redox biology and warrant that any clinical trials must take into consideration the redox threshold, flux, subcellular localization, and cell types. For example, ascorbate was first hypothesized to be an effective anticancer agent in 1972 by Ewan Cameron and Linus Pauling (45, 46, 232). However, early clinical trials by Moertel (67, 204) showed that ascorbate is ineffective in treating advanced cancers. Although the research community was quick to lose interest in ascorbate as a cancer-therapy agent, it is important to note that the oral delivery of ascorbate was insufficient to achieve a therapeutic dose level in the plasma. Recent evidence suggests that intravascular delivery of ascorbate indeed showed a much higher plasma concentration of ascorbate that exhibited a positive correlation with inhibition in tumor growth in human, rat, and murine tumor xenografts (58). Additionally, antioxidants are often chosen as therapy agents based on their availability and ease of delivery (312). Many studies have used vitamin E, which has both antioxidant and prooxidant effects (238). This dual effect of certain antioxidants warrants that extra care must be taken in selecting antioxidants for therapeutic purposes. It is believed that a more-careful development of targeted antioxidant-based therapy could be more rewarding.

We believe the literature discussed in this review article will foster an innovative research frontier focusing on redox control of the cell cycle in health and disease. Newer and more-effective antioxidants targeted at the redox control of the cell cycle could provide additional therapy options to treat proliferative disorders.

Acknowledgments

The first two authors contributed equally to this work. We thank Drs. Jennifer Nickerson-Gass and Venkatasubbaiah A. Venkatesha for critical reading of the manuscript and Mr. Gareth Smith for help with illustrations. Funding from NIH CA 111365 and McCord Research foundation supported this work.

References

1. Abergel RP, Pizzurro D, Meeker CA, Lask G, Matsuoka LY, Minor RR, Chu ML, and Uitto J. Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblast cultures. *J Invest Dermatol* 84: 384–390, 1985.
2. AHA. American Heart Association. <http://www.americanheart.org/presenter.jhtml?identifier=4478>. Accessed 2009
3. Ahuja P, Sdek P, and MacLellan WR. Cardiac myocyte cell cycle control in development, disease, and regeneration. *Physiol Rev* 87: 521–544, 2007.
4. Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, and Pestell RG. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. *J Biol Chem* 270: 23589–23597, 1995.

5. Aleem E and Kaldis P. Mouse models of cell cycle regulators: new paradigms. *Results Probl Cell Differ* 42: 271–328, 2006.
6. Anscher MS, Kong FM, Marks LB, Bentel GC, and Jirtle RL. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. *Int J Radiat Oncol Biol Phys* 37: 253–258, 1997.
7. Atzori C, Ghetti B, Piva R, Srinivasan AN, Zolo P, Delisle MB, Mirra SS, and Migheli A. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. *J Neuropathol Exp Neurol* 60: 1190–1197, 2001.
8. Baas AS and Berk BC. Differential activation of mitogen-activated protein kinases by H₂O₂ and O²⁻ in vascular smooth muscle cells. *Circ Res* 77: 29–36, 1995.
9. Bae YS, Sung JY, Kim OS, Kim YJ, Hur KC, Kazlauskas A, and Rhee SG. Platelet-derived growth factor-induced H(2)O(2) production requires the activation of phosphatidylinositol 3-kinase. *J Biol Chem* 275: 10527–10531, 2000.
10. Banerjee S, Smallwood A, Nargund G, and Campbell S. Placental morphogenesis in pregnancies with Down's syndrome might provide a clue to pre-eclampsia. *Placenta* 23: 172–174, 2002.
11. Barcellos-Hoff MH and Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. *Cancer Res* 60: 1254–1260, 2000.
12. Bartkova J, Gron B, Dabelsteen E, and Bartek J. Cell-cycle regulatory proteins in human wound healing. *Arch Oral Biol* 48: 125–132, 2003.
13. Bartosz G. Reactive oxygen species: destroyers or messengers? *Biochem Pharmacol* 77: 1303–1315, 2009.
14. Bashan N, Kovsan J, Kachko I, Ovadia H, and Rudich A. Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. *Physiol Rev* 89: 27–71, 2009.
15. Bauer G. Reactive oxygen and nitrogen species: efficient, selective, and interactive signals during intercellular induction of apoptosis. *Anticancer Res* 20: 4115–4139, 2000.
16. Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, and Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. *Cancer Res* 66: 794–802, 2006.
17. Beckman JS and Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. *Am J Physiol* 271: C1424–C1437, 1996.
18. Behl C, Davis JB, Lesley R, and Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. *Cell* 77: 817–827, 1994.
19. Behrend L, Henderson G, and Zwacka RM. Reactive oxygen species in oncogenic transformation. *Biochem Soc Trans* 31: 1441–1444, 2003.
20. Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, Nadal-Ginard B, Silvestri F, Leri A, Beltrami CA, and Anversa P. Evidence that human cardiac myocytes divide after myocardial infarction. *N Engl J Med* 344: 1750–1757, 2001.
21. Bennett MR, Littlewood TD, Hancock DC, Evan GI, and Newby AC. Down-regulation of the c-myc proto-oncogene in inhibition of vascular smooth-muscle cell proliferation: a signal for growth arrest? *Biochem J* 302: 701–708, 1994.
22. Bennett MR, Macdonald K, Chan SW, Boyle JJ, and Weissberg PL. Cooperative interactions between RB and

- p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques. *Circ Res* 82: 704–712, 1998.
23. Bergeron A, Soler P, Kambouchner M, Loiseau P, Milleron B, Valeyre D, Hance AJ, and Tazi A. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. *Eur Respir J* 22: 69–76, 2003.
 24. Blair AS, Hajdуч E, Litherland GJ, and Hundal HS. Regulation of glucose transport and glycogen synthesis in L6 muscle cells during oxidative stress: evidence for cross-talk between the insulin and SAPK2/p38 mitogen-activated protein kinase signaling pathways. *J Biol Chem* 274: 36293–36299, 1999.
 25. Bloch-Damti A and Bashan N. Proposed mechanisms for the induction of insulin resistance by oxidative stress. *Antioxid Redox Signal* 7: 1553–1567, 2005.
 26. Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. *Exp Clin Endocrinol Diabetes* 111: 121–124, 2003.
 27. Bokoch GM and Knaus UG. NADPH oxidases: not just for leukocytes anymore! *Trends Biochem Sci* 28: 502–508, 2003.
 28. Brandeis M, Rosewell I, Carrington M, Crompton T, Jacobs MA, Kirk J, Gannon J, and Hunt T. Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. *Proc Natl Acad Sci U S A* 95: 4344–4349, 1998.
 29. Braun-Dullaeus RC, Mann MJ, and Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. *Circulation* 98: 82–89, 1998.
 30. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, and Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. *Nature* 351: 714–718, 1991.
 31. Broughton G 2nd, Janis JE, and Attinger CE. Wound healing: an overview. *Plast Reconstr Surg* 117: 1e–S–32e–S, 2006.
 32. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, and Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med* 345: 1583–1592, 2001.
 33. Brownawell AM, Kops GJ, Macara IG, and Burgering BM. Inhibition of nuclear import by protein kinase B (Akt) regulates the subcellular distribution and activity of the forkhead transcription factor AFX. *Mol Cell Biol* 21: 3534–3546, 2001.
 34. Bruck R, Schey R, Aeed H, Hochman A, Genina O, and Pines M. A protective effect of pyrrolidine dithiocarbamate in a rat model of liver cirrhosis. *Liver Int* 24: 169–176, 2004.
 35. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, and Greenberg ME. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. *Science* 303: 2011–2015, 2004.
 36. Buettner GR, Ng CF, Wang M, Rodgers VG, and Schafer FQ. A new paradigm: manganese superoxide dismutase influences the production of H₂O₂ in cells and thereby their biological state. *Free Radic Biol Med* 41: 1338–1350, 2006.
 37. Burch PM and Heintz NH. Redox regulation of cell-cycle re-entry: cyclin D1 as a primary target for the mitogenic effects of reactive oxygen and nitrogen species. *Antioxid Redox Signal* 7: 741–751, 2005.
 38. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. *Free Radic Biol Med* 18: 775–794, 1995.
 39. Burdon RH and Gill V. Cellularly generated active oxygen species and HeLa cell proliferation. *Free Radic Res Commun* 19: 203–213, 1993.
 40. Burdon RH, Gill V, and Rice-Evans C. Cell proliferation and oxidative stress. *Free Radic Res Commun* 7: 149–159, 1989.
 41. Burdon RH, Gill V, and Rice-Evans C. Oxidative stress and tumour cell proliferation. *Free Radic Res Commun* 11: 65–76, 1990.
 42. Burton PB, Yacoub MH, and Barton PJ. Cyclin-dependent kinase inhibitor expression in human heart failure: a comparison with fetal development. *Eur Heart J* 20: 604–611, 1999.
 43. Busuttill RA, Rubio M, Dolle ME, Campisi J, and Vijg J. Oxygen accelerates the accumulation of mutations during the senescence and immortalization of murine cells in culture. *Aging Cell* 2: 287–294, 2003.
 44. Calderon M, Lawrence WT, and Banes AJ. Increased proliferation in keloid fibroblasts wounded in vitro. *J Surg Res* 61: 343–347, 1996.
 45. Cameron E and Pauling L. Ascorbic acid and the glycosaminoglycans: an orthomolecular approach to cancer and other diseases. *Oncology* 27: 181–192, 1973.
 46. Cameron E and Rotman D. Ascorbic acid, cell proliferation, and cancer. *Lancet* 1: 542, 1972.
 47. Campisi J. Aging, tumor suppression and cancer: high wire-act! *Mech Ageing Dev* 126: 51–58, 2005.
 48. Campisi J. Cancer, aging and cellular senescence. *In Vivo* 14: 183–188, 2000.
 49. Campisi J. Replicative senescence: an old lives' tale? *Cell* 84: 497–500, 1996.
 50. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. *Cell* 120: 513–522, 2005.
 51. Campisi J. Suppressing cancer: the importance of being senescent. *Science* 309: 886–887, 2005.
 52. Cantin AM, Hubbard RC, and Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. *Am Rev Respir Dis* 139: 370–372, 1989.
 53. Carpenter AF, Carpenter PW, and Markesbery WR. Morphometric analysis of microglia in Alzheimer's disease. *J Neuropathol Exp Neurol* 52: 601–608, 1993.
 54. CDC. National Center for Chronic Disease Prevention and Health Promotion <http://www.cdc.gov/diabetes/faq/basics.htm>. Accessed 2008
 55. Ceolotto G, Papparella I, Lenzini L, Sartori M, Mazzoni M, Iori E, Franco L, Gallo A, de Kreutzenberg SV, Tiengo A, Pessina AC, Avogaro A, and Semplicini A. Insulin generates free radicals in human fibroblasts ex vivo by a protein kinase C-dependent mechanism, which is inhibited by pravastatin. *Free Radic Biol Med* 41: 473–483, 2006.
 56. Ceradini DJ, Yao D, Grogan RH, Callaghan MJ, Edelstein D, Brownlee M, and Gurtner GC. Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. *J Biol Chem* 283: 10930–10938, 2008.
 57. Chen JH, Tseng TH, Ho YC, Lin HH, Lin WL, and Wang CJ. Gaseous nitrogen oxides stimulate cell cycle progression by retinoblastoma phosphorylation via activation of cyclins/Cdks [correction]. *Toxicol Sci* 76: 83–90, 2003.
 58. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, and Levine M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. *Proc Natl Acad Sci U S A* 105: 11105–11109, 2008.

59. Chen Z, Odstrcil EA, Tu BP, and McKnight SL. Restriction of DNA replication to the reductive phase of the metabolic cycle protects genome integrity. *Science* 316: 1916–1919, 2007.
60. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, and Sherr CJ. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. *EMBO J* 18: 1571–1583, 1999.
61. Chiumiento A, Lamponi S, Barbucci R, Dominguez A, Perez Y, and Villalonga R. Immobilizing Cu,Zn-superoxide dismutase in hydrogels of carboxymethylcellulose improves its stability and wound healing properties. *Biochemistry (Mosc)* 71: 1324–1328, 2006.
62. Church SL, Grant JW, Ridnour LA, Oberley LW, Swanson PE, Meltzer PS, and Trent JM. Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. *Proc Natl Acad Sci U S A* 90: 3113–3117, 1993.
63. Ciemerych MA and Sicinski P. Cell cycle in mouse development. *Oncogene* 24: 2877–2898, 2005.
64. Conour JE, Graham WV, and Gaskins HR. A combined in vitro/bioinformatic investigation of redox regulatory mechanisms governing cell cycle progression. *Physiol Genomics* 18: 196–205, 2004.
65. Coyle JT and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. *Science* 262: 689–695, 1993.
66. Cozar-Castellano I, Takane KK, Bottino R, Balamurugan AN, and Stewart AF. Induction of beta-cell proliferation and retinoblastoma protein phosphorylation in rat and human islets using adenovirus-mediated transfer of cyclin-dependent kinase-4 and cyclin D1. *Diabetes* 53: 149–159, 2004.
67. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, and Frytak S. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial. *N Engl J Med* 301: 687–690, 1979.
68. Cross DA, Alessi DR, Cohen P, Andjelkovich M, and Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature* 378: 785–789, 1995.
69. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, and Sorescu D. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. *Circ Res* 97: 900–907, 2005.
70. Culotta E and Koshland DE Jr. NO news is good news. *Science* 258: 1862–1865, 1992.
71. Datto MB, Yu Y, and Wang XF. Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. *J Biol Chem* 270: 28623–28628, 1995.
72. De Minicis S and Brenner DA. NOX in liver fibrosis. *Arch Biochem Biophys* 462: 266–272, 2007.
73. Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, and DeFronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. *Diabetologia* 37: 1025–1035, 1994.
74. Delanian S and Lefaix JL. The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. *Radiother Oncol* 73: 119–131, 2004.
75. Deng C, Zhang P, Harper JW, Elledge SJ, and Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G₁ checkpoint control. *Cell* 82: 675–684, 1995.
76. DeYulia GJ Jr, Carcamo JM, Borquez-Ojeda O, Shelton CC, and Golde DW. Hydrogen peroxide generated extracellularly by receptor-ligand interaction facilitates cell signaling. *Proc Natl Acad Sci U S A* 102: 5044–5049, 2005.
77. Di Mascio P, Murphy ME, and Sies H. Antioxidant defense systems: the role of carotenoids, tocopherols, and thiols. *Am J Clin Nutr* 53: 194S–200S, 1991.
78. Diez J, Panizo A, Hernandez M, Galindo MF, Cenarruzabeitia E, and Pardo Mindan FJ. Quinapril inhibits c-Myc expression and normalizes smooth muscle cell proliferation in spontaneously hypertensive rats. *Am J Hypertens* 10: 1147–1152, 1997.
79. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, and Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. *Nature* 399: 601–605, 1999.
80. Dkhissi F, Raynal S, and Lawrence DA. Altered complex formation between p21waf, p27kip and their partner G1 cyclins determines the stimulatory or inhibitory transforming growth factor-beta1 growth response of human fibroblasts. *Int J Oncol* 14: 905–910, 1999.
81. Dong-Le Bourhis X, Berthois Y, Millot G, Degeorges A, Sylvi M, Martin PM, and Calvo F. Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. *Int J Cancer* 71: 42–48, 1997.
82. Duilio C, Ambrosio G, Kuppusamy P, DiPaula A, Becker LC, and Zweier JL. Neutrophils are primary source of O₂ radicals during reperfusion after prolonged myocardial ischemia. *Am J Physiol Heart Circ Physiol* 280: H2649–H2657, 2001.
83. Dulic V, Beney GE, Frebourg G, Drullinger LF, and Stein GH. Uncoupling between phenotypic senescence and cell cycle arrest in aging p21-deficient fibroblasts. *Mol Cell Biol* 20: 6741–6754, 2000.
84. Dunphy WG and Kumagai A. The cdc25 protein contains an intrinsic phosphatase activity. *Cell* 67: 189–196, 1991.
85. Dzau VJ, Braun-Dullaeus RC, and Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. *Nat Med* 8: 1249–1256, 2002.
86. Dzau VJ, Gibbons GH, and Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. *Hypertension* 18: II100–II115, 1991.
87. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, and Taylor JO. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. *JAMA* 262: 2551–2556, 1989.
88. Evans JL, Goldfine ID, Maddux BA, and Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? *Diabetes* 52: 1–8, 2003.
89. Fantl V, Stamp G, Andrews A, Rosewell I, and Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. *Genes Dev* 9: 2364–2372, 1995.
90. Fatokun AA, Stone TW, and Smith RA. Oxidative stress in neurodegeneration and available means of protection. *Front Biosci* 13: 3288–3311, 2008.
91. Fatrai S, Elghazi L, Balcazar N, Cras-Meneur C, Krits I, Kiyokawa H, and Bernal-Mizrachi E. Akt induces beta-cell proliferation by regulating cyclin D1, cyclin D2, and p21

- levels and cyclin-dependent kinase-4 activity. *Diabetes* 55: 318–325, 2006.
92. Fearnley JM and Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. *Brain* 114: 2283–2301, 1991.
 93. Fernandes AP and Holmgren A. Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system. *Antioxid Redox Signal* 6: 63–74, 2004.
 94. Finch CE. The biology of aging in model organisms. *Alzheimer Dis Assoc Disord* 17(suppl 2): S39–S41, 2003.
 95. Finkel T. Oxidant signals and oxidative stress. *Curr Opin Cell Biol* 15: 247–254, 2003.
 96. Finkel T and Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. *Nature* 408: 239–247, 2000.
 97. Fisher CJ and Goswami PC. Mitochondria-targeted antioxidant enzyme activity regulates radioresistance in human pancreatic cancer cells. *Cancer Biol Ther* 7: 1271–1279, 2008.
 98. Folz RJ and Crapo JD. Extracellular superoxide dismutase (SOD3): tissue-specific expression, genomic characterization, and computer-assisted sequence analysis of the human EC SOD gene. *Genomics* 22: 162–171, 1994.
 99. Frendo JL, Therond P, Bird T, Massin N, Muller F, Guibourdenche J, Luton D, Vidaud M, Anderson WB, and Evain-Brion D. Overexpression of copper zinc superoxide dismutase impairs human trophoblast cell fusion and differentiation. *Endocrinology* 142: 3638–3648, 2001.
 100. Frendo JL, Therond P, Guibourdenche J, Vidaud M, and Evain-Brion D. Implication of copper zinc superoxide dismutase (SOD-1) in human placenta development. *Ann N Y Acad Sci* 973: 297–301, 2002.
 101. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. *J Biol Chem* 275: 2247–2250, 2000.
 102. Fu XD, Cui YH, Lin GP, and Wang TH. Non-genomic effects of 17beta-estradiol in activation of the ERK1/ERK2 pathway induces cell proliferation through upregulation of cyclin D1 expression in bovine artery endothelial cells. *Gynecol Endocrinol* 23: 131–137, 2007.
 103. Galaris D, Skiada V, and Barbouti A. Redox signaling and cancer: the role of "labile" iron. *Cancer Lett* 266: 21–29, 2008.
 104. Gao F, Kinnula VL, Myllarniemi M, and Oury TD. Extracellular superoxide dismutase in pulmonary fibrosis. *Antioxid Redox Signal* 10: 343–354, 2008.
 105. Gao Z, Sarsour EH, Kalen AL, Li L, Kumar MG, and Goswami PC. Late ROS accumulation and radiosensitivity in SOD1-overexpressing human glioma cells. *Free Radic Biol Med* 45: 1501–1509, 2008.
 106. Ge X, Yu Q, Qi W, Shi X, and Zhai Q. Chronic insulin treatment causes insulin resistance in 3T3-L1 adipocytes through oxidative stress. *Free Radic Res* 42: 582–591, 2008.
 107. Georgia S and Bhushan A. Beta cell replication is the primary mechanism for maintaining postnatal beta cell mass. *J Clin Invest* 114: 963–968, 2004.
 108. Gius D and Spitz DR. Redox signaling in cancer biology. *Antioxid Redox Signal* 8: 1249–1252, 2006.
 109. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, and Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. *Ann Neurol* 41: 17–24, 1997.
 110. Gorbunova V, Seluanov A, and Pereira-Smith OM. Evidence that high telomerase activity may induce a senescent-like growth arrest in human fibroblasts. *J Biol Chem* 278: 7692–7698, 2003.
 111. Goswami PC, Sheren J, Albee LD, Parsian A, Sim JE, Ridnour LA, Higashikubo R, Gius D, Hunt CR, and Spitz DR. Cell cycle-coupled variation in topoisomerase IIalpha mRNA is regulated by the 3'-untranslated region: possible role of redox-sensitive protein binding in mRNA accumulation. *J Biol Chem* 275: 38384–38392, 2000.
 112. Grana X and Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). *Oncogene* 11: 211–219, 1995.
 113. Grankvist K, Marklund SL, and Taljedal IB. CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. *Biochem J* 199: 393–398, 1981.
 114. Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, and Pepine CJ. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells: a potential treatment for restenosis? *Circulation* 89: 1511–1517, 1994.
 115. Griendling KK, Minieri CA, Ollerenshaw JD, and Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. *Circ Res* 74: 1141–1148, 1994.
 116. Guo K, Andres V, and Walsh K. Nitric oxide-induced downregulation of Cdk2 activity and cyclin A gene transcription in vascular smooth muscle cells. *Circulation* 97: 2066–2072, 1998.
 117. Hagiwara SI, Ishii Y, and Kitamura S. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. *Am J Respir Crit Care Med* 162: 225–231, 2000.
 118. Halliwell B. Oxidative stress and cancer: have we moved forward? *Biochem J* 401: 1–11, 2007.
 119. Halliwell B. Oxidative stress and neurodegeneration: where are we now? *J Neurochem* 97: 1634–1658, 2006.
 120. Halliwell B and Gutteridge J. Antioxidant defence enzymes: catalases. In: *Free radicals in biology and medicine*. 3rd ed. Oxford: Oxford University Press, 1999, p 936.
 121. Halliwell B and Gutteridge JM. Biologically relevant metal ion-dependent hydroxyl radical generation: an update. *FEBS Lett* 307: 108–112, 1992.
 122. Hansen LL, Ikeda Y, Olsen GS, Busch AK, and Mosthaf L. Insulin signaling is inhibited by micromolar concentrations of H(2)O(2): evidence for a role of H(2)O(2) in tumor necrosis factor alpha-mediated insulin resistance. *J Biol Chem* 274: 25078–25084, 1999.
 123. Harman D. Aging: a theory based on free radical and radiation chemistry. *J Gerontol* 11: 298–300, 1956.
 124. Harris N, Costa V, MacLean M, Mollapour M, Moradas-Ferreira P, and Piper PW. MnSOD overexpression extends the yeast chronological (G(0)) life span but acts independently of Sir2p histone deacetylase to shorten the replicative life span of dividing cells. *Free Radic Biol Med* 34: 1599–1606, 2003.
 125. He T, Weintraub NL, Goswami PC, Chatterjee P, Flaherty DM, Domann FE, and Oberley LW. Redox factor-1 contributes to the regulation of progression from G₀/G₁ to S by PDGF in vascular smooth muscle cells. *Am J Physiol Heart Circ Physiol* 285: H804–H812, 2003.
 126. Heinonen OP and Albanes D. The effect of vitamin E and beta carotene on the incidence of lung cancer and other

- cancers in male smokers: the Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. *N Engl J Med* 330: 1029–1035, 1994.
127. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, and Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G₀/G₁-to-S-phase transition. *Mol Cell Biol* 19: 2690–2698, 1999.
 128. Hohegger H, Takeda S, and Hunt T. Cyclin-dependent kinases and cell-cycle transitions: does one fit all? *Natl Rev Mol Cell Biol* 9: 910–916, 2008.
 129. Hoffman A, Spetner LM, and Burke M. Ramifications of a redox switch within a normal cell: its absence in a cancer cell. *Free Radic Biol Med* 45: 265–268, 2008.
 130. Holmgren A. Redox regulation by thioredoxin and thioredoxin reductase. *Biofactors* 11: 63–64, 2000.
 131. Hori M and Nishida K. Oxidative stress and left ventricular remodeling after myocardial infarction. *Cardiovasc Res* 81: 457–464, 2009.
 132. Hou ZQ, Li HL, Zhao JJ, and Li GW. [Impairment of pancreatic islet beta cell function induced by intermittent high glucose through oxidative and endoplasmic reticulum stress: experiment with rat pancreatic islet beta cells]. *Zhonghua Yi Xue Za Zhi* 88: 2002–2004, 2008.
 133. Houstis N, Rosen ED, and Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. *Nature* 440: 944–948, 2006.
 134. Hutter DE, Till BG, and Greene JJ. Redox state changes in density-dependent regulation of proliferation. *Exp Cell Res* 232: 435–438, 1997.
 135. Inoshima I, Kuwano K, Hamada N, Yoshimi M, Maeyama T, Hagimoto N, Nakanishi Y, and Hara N. Induction of CDK inhibitor p21 gene as a new therapeutic strategy against pulmonary fibrosis. *Am J Physiol Lung Cell Mol Physiol* 286: L727–L733, 2004.
 136. Ishida A, Sasaguri T, Kosaka C, Nojima H, and Ogata J. Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells. *J Biol Chem* 272: 10050–10057, 1997.
 137. Iyer SS, Ramirez AM, Ritzenthaler JD, Torres-Gonzalez E, Roser-Page S, Mora AL, Brigham KL, Jones DP, Roman J, and Rojas M. Oxidation of extracellular cysteine/cystine redox state in bleomycin-induced lung fibrosis. *Am J Physiol Lung Cell Mol Physiol* 296: L37–L45, 2009.
 138. Jackson RM, Helton ES, Viera L, and Ohman T. Survival, lung injury, and lung protein nitration in heterozygous MnSOD knockout mice in hyperoxia. *Exp Lung Res* 25: 631–646, 1999.
 139. Jeon SM, Bok SH, Jang MK, Lee MK, Nam KT, Park YB, Rhee SJ, and Choi MS. Antioxidative activity of naringin and lovastatin in high cholesterol-fed rabbits. *Life Sci* 69: 2855–2866, 2001.
 140. Jeong DW, Kim EH, Kim TS, Chung YW, Kim H, and Kim IY. Different distributions of selenoprotein W and thioredoxin during postnatal brain development and embryogenesis. *Mol Cells* 17: 156–159, 2004.
 141. Jordana M, Schulman J, McSharry C, Irving LB, Newhouse MT, Jordana G, and Gauldie J. Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. *Am Rev Respir Dis* 137: 579–584, 1988.
 142. Kajstura J, Leri A, Finato N, Di Loreto C, Beltrami CA, and Anversa P. Myocyte proliferation in end-stage cardiac failure in humans. *Proc Natl Acad Sci U S A* 95: 8801–8805, 1998.
 143. Kalen AL, Sarsour EH, Venkataraman S, and Goswami PC. Mn-superoxide dismutase overexpression enhances G₂ accumulation and radioresistance in human oral squamous carcinoma cells. *Antioxid Redox Signal* 8: 1273–1281, 2006.
 144. Kang SK, Rabbani ZN, Folz RJ, Golson ML, Huang H, Yu D, Samulski TS, Dewhirst MW, Anscher MS, and Vujaskovic Z. Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. *Int J Radiat Oncol Biol Phys* 57: 1056–1066, 2003.
 145. Kardami E. Stimulation and inhibition of cardiac myocyte proliferation in vitro. *Mol Cell Biochem* 92: 129–135, 1990.
 146. Kawamura N. Cytochemical and quantitative study of protein-bound sulfhydryl and disulfide groups in eggs of *Arbacia* during the first cleavage. *Exp Cell Res* 20: 127–138, 1960.
 147. Kim KY, Rhim T, Choi I, and Kim SS. N-Acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity. *J Biol Chem* 276: 40591–40598, 2001.
 148. Kinnula VL. Redox imbalance and lung fibrosis. *Antioxid Redox Signal* 10: 249–252, 2008.
 149. Kinnula VL, Fattman CL, Tan RJ, and Oury TD. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. *Am J Respir Crit Care Med* 172: 417–422, 2005.
 150. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, and Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). *Cell* 85: 721–732, 1996.
 151. Klebanoff SJ. Myeloperoxidase: friend and foe. *J Leukoc Biol* 77: 598–625, 2005.
 152. Klein JA and Ackerman SL. Oxidative stress, cell cycle, and neurodegeneration. *J Clin Invest* 111: 785–793, 2003.
 153. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffey PJ, Huang TT, Bos JL, Medema RH, and Burgering BM. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. *Nature* 419: 316–321, 2002.
 154. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffey PJ, Lam EW, and Burgering BM. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. *Mol Cell Biol* 22: 2025–2036, 2002.
 155. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, and Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. *Nature* 413: 83–86, 2001.
 156. Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A, Bonner-Weir S, and Sharpless NE. p16INK4a induces an age-dependent decline in islet regenerative potential. *Nature* 443: 453–457, 2006.
 157. Krtolica A, Parrinello S, Lockett S, Desprez PY, and Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. *Proc Natl Acad Sci U S A* 98: 12072–12077, 2001.
 158. Kushner JA, Ciemerych MA, Sicinska E, Wartschow LM, Teta M, Long SY, Sicinski P, and White MF. Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. *Mol Cell Biol* 25: 3752–3762, 2005.
 159. Kwon SH, Pimentel DR, Remondino A, Sawyer DB, and Colucci WS. H₂O₂ regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. *J Mol Cell Cardiol* 35: 615–621, 2003.
 160. Kyaw M, Yoshizumi M, Tsuchiya K, Izawa Y, Kanematsu Y, Fujita Y, Ali N, Ishizawa K, Yamauchi A, and Tamaki T. Antioxidant effects of stereoisomers of N-acetylcysteine (NAC), L-NAC and D-NAC, on angiotensin II-stimulated

- MAP kinase activation and vascular smooth muscle cell proliferation. *J Pharmacol Sci* 95: 483–486, 2004.
161. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, and Harlow E. New functional activities for the p21 family of CDK inhibitors. *Genes Dev* 11: 847–862, 1997.
 162. Land SC and Wilson SM. Redox regulation of lung development and perinatal lung epithelial function. *Antioxid Redox Signal* 7: 92–107, 2005.
 163. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, and Griendling KK. Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. *Circ Res* 88: 888–894, 2001.
 164. Latres E, Malumbres M, Sotillo R, Martin J, Ortega S, Martin-Caballero J, Flores JM, Cordon-Cardo C, and Barbacid M. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. *EMBO J* 19: 3496–3506, 2000.
 165. Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves A, Levy E, Goldwasser F, Panis Y, Soubrane O, Weill B, and Batteux F. Controlling tumor growth by modulating endogenous production of reactive oxygen species. *Cancer Res* 65: 948–956, 2005.
 166. Lebovitz RM, Zhang H, Vogel H, Cartwright J Jr, Dionne L, Lu N, Huang S, and Matzuk MM. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. *Proc Natl Acad Sci U S A* 93: 9782–9787, 1996.
 167. Levonen AL, Patel RP, Brookes P, Go YM, Jo H, Parthasarathy S, Anderson PG, and Darley-Usmar VM. Mechanisms of cell signaling by nitric oxide and peroxynitrite: from mitochondria to MAP kinases. *Antioxid Redox Signal* 3: 215–29, 2001.
 168. Li JJ, Oberley LW, St Clair DK, Ridnour LA, and Oberley TD. Phenotypic changes induced in human breast cancer cells by overexpression of manganese-containing superoxide dismutase. *Oncogene* 10: 1989–2000, 1995.
 169. Li JM and Brooks G. Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy? *Eur Heart J* 20: 406–420, 1999.
 170. Li JM and Shah AM. ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. *J Am Soc Nephrol* 14: S221–S226, 2003.
 171. Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Berger C, Chan PH, Wallace DC, and Epstein CJ. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. *Nat Genet* 11: 376–381, 1995.
 172. Lieber CS. Relationships between nutrition, alcohol use, and liver disease. *Alcohol Res Health* 27: 220–231, 2003.
 173. Lindner V and Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. *Proc Natl Acad Sci U S A* 88: 3739–3743, 1991.
 174. Liu JQ, Zelko IN, Erbynn EM, Sham JS, and Folz RJ. Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). *Am J Physiol Lung Cell Mol Physiol* 290: L2–L10, 2006.
 175. Liu M, Wikonkal NM, and Brash DE. Induction of cyclin-dependent kinase inhibitors and G(1) prolongation by the chemopreventive agent N-acetylcysteine. *Carcinogenesis* 20: 1869–1872, 1999.
 176. Liu Y, Cigola E, Cheng W, Kajstura J, Olivetti G, Hintze TH, and Anversa P. Myocyte nuclear mitotic division and programmed myocyte cell death characterize the cardiac myopathy induced by rapid ventricular pacing in dogs. *Lab Invest* 73: 771–787, 1995.
 177. Loflin J, Lopez N, Whanger PD, and Kioussi C. Selenoprotein W during development and oxidative stress. *J Inorg Biochem* 100: 1679–1684, 2006.
 178. Luo S, Benathan M, Raffoul W, Panizzon RG, and Egloff DV. Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. *Plast Reconstr Surg* 107: 87–96, 2001.
 179. Lyle AN and Griendling KK. Modulation of vascular smooth muscle signaling by reactive oxygen species. *Physiology (Bethesda)* 21: 269–280, 2006.
 180. Mackay DJ and Hall A. Rho GTPases. *J Biol Chem* 273: 20685–20688, 1998.
 181. Maejima Y, Adachi S, Ito H, Nobori K, Tamamori-Adachi M, and Isobe M. Nitric oxide inhibits ischemia/reperfusion-induced myocardial apoptosis by modulating cyclin A-associated kinase activity. *Cardiovasc Res* 59: 308–320, 2003.
 182. Mahadev K, Zilbering A, Zhu L, and Goldstein BJ. Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances the early insulin action cascade. *J Biol Chem* 276: 21938–21942, 2001.
 183. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, and Reidy MA. Production of transforming growth factor beta 1 during repair of arterial injury. *J Clin Invest* 88: 904–910, 1991.
 184. Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S, Dubus P, and Barbacid M. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. *Cell* 118: 493–504, 2004.
 185. Mares J and Welsh M. Expression of certain anti-proliferative and growth-related genes in isolated mouse pancreatic islets: analysis by polymerase chain reaction. *Diabetes Metab* 19: 315–320, 1993.
 186. Marshall HE and Stamler JS. Exhaled nitric oxide (NO), NO synthase activity, and regulation of nuclear factor (NF)-kappaB. *Am J Respir Cell Mol Biol* 21: 296–297, 1999.
 187. Martin M, Lefaix J, and Delanian S. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? *Int J Radiat Oncol Biol Phys* 47: 277–290, 2000.
 188. Martinez Munoz C, Post JA, Verkleij AJ, Verrips CT, and Boonstra J. The effect of hydrogen peroxide on the cyclin D expression in fibroblasts. *Cell Mol Life Sci* 58: 990–996, 2001.
 189. Massey V, Strickland S, Mayhew SG, Howell LG, Engel PC, Matthews RG, Schuman M, and Sullivan PA. The production of superoxide anion radicals in the reaction of reduced flavins and flavoproteins with molecular oxygen. *Biochem Biophys Res Commun* 36: 891–897, 1969.
 190. Mates JM and Sanchez-Jimenez FM. Role of reactive oxygen species in apoptosis: implications for cancer therapy. *Int J Biochem Cell Biol* 32: 157–170, 2000.
 191. Matsui M, Oshima M, Oshima H, Takaku K, Maruyama T, Yodoi J, and Taketo MM. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. *Dev Biol* 178: 179–185, 1996.
 192. Matsuoka Y, Picciano M, La Francois J, and Duff K. Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. *Neuroscience* 104: 609–613, 2001.
 193. Mattson MP and Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. *J Clin Invest* 107: 247–254, 2001.

194. Matzuk MM, Dionne L, Guo Q, Kumar TR, and Lebovitz RM. Ovarian function in superoxide dismutase 1 and 2 knockout mice. *Endocrinology* 139: 4008–4011, 1998.
195. Maurizio P and Novo E. Nrfl gene expression in the liver: a single gene linking oxidative stress to NAFLD, NASH and hepatic tumours. *J Hepatol* 43: 1096–1097, 2005.
196. McCord JM and Fridovich I. Superoxide dismutase: an enzymic function for erythrocyte (hemocuprein). *J Biol Chem* 244: 6049–6055, 1969.
197. McShea A, Harris PL, Webster KR, Wahl AF, and Smith MA. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. *Am J Pathol* 150: 1933–1939, 1997.
198. Medema RH, Kops GJ, Bos JL, and Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. *Nature* 404: 782–787, 2000.
199. Menon SG, Coleman MC, Walsh SA, Spitz DR, and Goswami PC. Differential susceptibility of nonmalignant human breast epithelial cells and breast cancer cells to thiol antioxidant-induced G₁-delay. *Antioxid Redox Signal* 7: 711–718, 2005.
200. Menon SG and Goswami PC. A redox cycle within the cell cycle: ring in the old with the new. *Oncogene* 26: 1101–1109, 2007.
201. Menon SG, Sarsour EH, Kalen AL, Venkataraman S, Hitchler MJ, Domann FE, Oberley LW, and Goswami PC. Superoxide signaling mediates N-acetyl-L-cysteine-induced G₁ arrest: regulatory role of cyclin D1 and manganese superoxide dismutase. *Cancer Res* 67: 6392–6399, 2007.
202. Menon SG, Sarsour EH, Spitz DR, Higashikubo R, Sturm M, Zhang H, and Goswami PC. Redox regulation of the G₁ to S phase transition in the mouse embryo fibroblast cell cycle. *Cancer Res* 63: 2109–2117, 2003.
203. Minamino T, Mitsialis SA, and Kourembanas S. Hypoxia extends the life span of vascular smooth muscle cells through telomerase activation. *Mol Cell Biol* 21: 3336–3342, 2001.
204. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, and Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized double-blind comparison. *N Engl J Med* 312: 137–141, 1985.
205. Monteiro HP, Ivaschenko Y, Fischer R, and Stern A. Inhibition of protein tyrosine phosphatase activity by diamide is reversed by epidermal growth factor in fibroblasts. *FEBS Lett* 295: 146–148, 1991.
206. Moustakas A, Souchelnytskyi S, and Heldin CH. Smad regulation in TGF- β signal transduction. *J Cell Sci* 114: 4359–4369, 2001.
207. Mudge BP, Harris C, Gilmont RR, Adamson BS, and Rees RS. Role of glutathione redox dysfunction in diabetic wounds. *Wound Repair Regen* 10: 52–58, 2002.
208. Murphy M. Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. *Nat Genet* 23: 481, 1999.
209. Murphy M, Stinnakre MG, Senamaud-Beaufort C, Winston NJ, Sweeney C, Kubelka M, Carrington M, Brechot C, and Sobczak-Thépot J. Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. *Nat Genet* 15: 83–86, 1997.
210. Nabel EG, Yang Z, Liptay S, San H, Gordon D, Haudenschild CC, and Nabel GJ. Recombinant platelet-derived growth factor B gene expression in porcine arteries induce intimal hyperplasia in vivo. *J Clin Invest* 91: 1822–1829, 1993.
211. Nagy Z, Esiri MM, Cato AM, and Smith AD. Cell cycle markers in the hippocampus in Alzheimer's disease. *Acta Neuropathol* 94: 6–15, 1997.
212. Nagy Z, Esiri MM, and Smith AD. Expression of cell division markers in the hippocampus in Alzheimer's disease and other neurodegenerative conditions. *Acta Neuropathol* 93: 294–300, 1997.
213. Napoli C, Lerman LO, de Nigris F, and Sica V. c-Myc oncoprotein: a dual pathogenic role in neoplasia and cardiovascular diseases? *Neoplasia* 4: 185–190, 2002.
214. Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. *Science* 258: 424–429, 1992.
215. Nguyen MD, Boudreau M, Kriz J, Couillard-Despres S, Kaplan DR, and Julien JP. Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1. *J Neurosci* 23: 2131–2140, 2003.
216. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, and Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature* 404: 787–790, 2000.
217. Nishio E and Watanabe Y. The involvement of reactive oxygen species and arachidonic acid in α 1-adrenoceptor-induced smooth muscle cell proliferation and migration. *Br J Pharmacol* 121: 665–670, 1997.
218. Nishiyama A, Masutani H, Nakamura H, Nishinaka Y, and Yodoi J. Redox regulation by thioredoxin and thioredoxin-binding proteins. *IUBMB Life* 52: 29–33, 2001.
219. Novo E, Marra F, Zamara E, Valfre di Bonzo L, Caligiuri A, Cannito S, Antonaci C, Colombatto S, Pinzani M, and Parola M. Dose dependent and divergent effects of superoxide anion on cell death, proliferation, and migration of activated human hepatic stellate cells. *Gut* 55: 90–97, 2006.
220. Nozato T, Ito H, Tamamori M, Adachi S, Abe S, Marumo F, and Hiroe M. G₁ cyclins are involved in the mechanism of cardiac myocyte hypertrophy induced by angiotensin II. *Jpn Circ J* 64: 595–601, 2000.
221. Nunomura A, Moreira PI, Lee HG, Zhu X, Castellani RJ, Smith MA, and Perry G. Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. *CNS Neurol Disord Drug Targets* 6: 411–423, 2007.
222. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, and Smith MA. Oxidative damage is the earliest event in Alzheimer disease. *J Neuropathol Exp Neurol* 60: 759–767, 2001.
223. Oberley LW. Anticancer therapy by overexpression of superoxide dismutase. *Antioxid Redox Signal* 3: 461–472, 2001.
224. Oberley LW and Buettner GR. Role of superoxide dismutase in cancer: a review. *Cancer Res* 39: 1141–1149, 1979.
225. Oberley TD, Oberley LW, Slattery AF, Lauchner LJ, and Elwell JH. Immunohistochemical localization of antioxidant enzymes in adult Syrian hamster tissues and during kidney development. *Am J Pathol* 137: 199–214, 1990.
226. Ojha N, Roy S, He G, Biswas S, Velayutham M, Khanna S, Kuppasamy P, Zweier JL, and Sen CK. Assessment of wound-site redox environment and the significance of Rac2 in cutaneous healing. *Free Radic Biol Med* 44: 682–691, 2008.
227. Oliveira CJ, Curcio MF, Moraes MS, Tsujita M, Travassos LR, Stern A, and Monteiro HP. The low molecular weight S-nitrosothiol, S-nitroso-N-acetylpenicillamine, promotes cell cycle progression in rabbit aortic endothelial cells. *Nitric Oxide* 18: 241–255, 2008.

228. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, and Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. *Cancer Res* 59: 5002–5011, 1999.
229. Omenn GS, Goodman G, Thornquist M, Grizzle J, Rosenstock L, Barnhart S, Balmes J, Cherniack MG, Cullen MR, Glass A, Keogh J, Meyskens F Jr, Valanis B, and Williams J Jr. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. *Cancer Res* 54: 2038s–2043s, 1994.
230. Orr WC and Sohal RS. Extension of life-span by overexpression of superoxide dismutase and catalase in *Drosophila melanogaster*. *Science* 263: 1128–1130, 1994.
231. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, Barbero JL, Malumbres M, and Barbacid M. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. *Nat Genet* 35: 25–31, 2003.
232. Padayatty SJ and Levine M. Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. *J Am Coll Nutr* 19: 423–425, 2000.
233. Papa S and Skulachev VP. Reactive oxygen species, mitochondria, apoptosis and aging. *Mol Cell Biochem* 174: 305–319, 1997.
234. Papaconstantinou J. Insulin/IGF-1 and ROS signaling pathway cross-talk in aging and longevity determination. *Mol Cell Endocrinol* 299: 89–100, 2009.
235. Paravicini TM and Touyz RM. Redox signaling in hypertension. *Cardiovasc Res* 71: 247–258, 2006.
236. Pardee AB. A restriction point for control of normal animal cell proliferation. *Proc Natl Acad Sci U S A* 71: 1286–1290, 1974.
237. Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, and Campisi J. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. *Nat Cell Biol* 5: 741–747, 2003.
238. Pearson P, Lewis SA, Britton J, Young IS, and Fogarty A. The pro-oxidant activity of high-dose vitamin E supplements in vivo. *BioDrugs* 20: 271–273, 2006.
239. Pennington JD, Jacobs KM, Sun L, Bar-Sela G, Mishra M, and Gius D. Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. *Curr Pharm Des* 13: 3368–3377, 2007.
240. Pennington JD, Wang TJ, Nguyen P, Sun L, Bisht K, Smart D, and Gius D. Redox-sensitive signaling factors as a novel molecular targets for cancer therapy. *Drug Resist Update* 8: 322–330, 2005.
241. Prat MI, Adamo AM, Gonzalez SA, Affranchino JL, Ikeda M, Matsubara E, Shoji M, Smith MA, Castano EM, and Morelli L. Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration. *Neurosci Lett* 326: 9–12, 2002.
242. Qiu P, Zhao TY, Li XJ, Liu SY, and Li XY. [Damage mechanism of intermittent exposure to high concentrations of glucose to beta cell lines (HIT-T15 cell)]. *Sichuan Da Xue Xue Bao Yi Xue Ban* 39: 69–71, 93, 2008.
243. Rabbani ZN, Anscher MS, Folz RJ, Archer E, Huang H, Chen L, Golson ML, Samulski TS, Dewhirst MW, and Vujaskovic Z. Overexpression of extracellular superoxide dismutase reduces acute radiation induced lung toxicity. *BMC Cancer* 5: 59, 2005.
244. Radunovic A and Leigh PN. ALSODatabase: database of SOD1 (and other) gene mutations in ALS on the Internet: European FALS Group and ALSOD Consortium. *Amyotroph Lateral Scler Other Motor Neuron Disord* 1: 45–49, 1999.
245. Raha S and Robinson BH. Mitochondria, oxygen free radicals, and apoptosis. *Am J Med Genet* 106: 62–70, 2001.
246. Rahman I, Yang SR, and Biswas SK. Current concepts of redox signaling in the lungs. *Antioxid Redox Signal* 8: 681–689, 2006.
247. Raina AK, Zhu X, Rottkamp CA, Monteiro M, Takeda A, and Smith MA. Cyclin' toward dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. *J Neurosci Res* 61: 128–133, 2000.
248. Raines EW. PDGF and cardiovascular disease. *Cytokine Growth Factor Rev* 15: 237–254, 2004.
249. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, and Barbacid M. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. *Nat Genet* 22: 44–52, 1999.
250. Rane SG and Reddy EP. Cell cycle control of pancreatic beta cell proliferation. *Front Biosci* 5: D1–19, 2000.
251. Ranganathan S and Bowser R. Alterations in G(1) to S phase cell-cycle regulators during amyotrophic lateral sclerosis. *Am J Pathol* 162: 823–835, 2003.
252. Ranjan P, Anathy V, Burch PM, Weirather K, Lambeth JD, and Heintz NH. Redox-dependent expression of cyclin D1 and cell proliferation by Nox1 in mouse lung epithelial cells. *Antioxid Redox Signal* 8: 1447–1459, 2006.
253. Rao GN and Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. *Circ Res* 70: 593–599, 1992.
254. Rao GN, Lassegue B, Griendling KK, and Alexander RW. Hydrogen peroxide stimulates transcription of c-jun in vascular smooth muscle cells: role of arachidonic acid. *Oncogene* 8: 2759–2764, 1993.
255. Rapkine L. Su les processus chimiques au cours de la division cellulaire. *Ann Physiol Physiochem Biol* 7: 382–418, 1931.
256. Rasik AM and Shukla A. Antioxidant status in delayed healing type of wounds. *Int J Exp Pathol* 81: 257–263, 2000.
257. Ravitz MJ, Yan S, Dolce C, Kinniburgh AJ, and Wenner CE. Differential regulation of p27 and cyclin D1 by TGF-beta and EGF in C3H 10T1/2 mouse fibroblasts. *J Cell Physiol* 168: 510–520, 1996.
258. Reiss K, Cheng W, Giordano A, De Luca A, Li B, Kajstura J, and Anversa P. Myocardial infarction is coupled with the activation of cyclins and cyclin-dependent kinases in myocytes. *Exp Cell Res* 225: 44–54, 1996.
259. Rhee SG, Bae YS, Lee SR, and Kwon J. Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. *Sci STKE* 2000: PE1, 2000.
260. Rhee SG, Chang TS, Bae YS, Lee SR, and Kang SW. Cellular regulation by hydrogen peroxide. *J Am Soc Nephrol* 14: S211–S215, 2003.
261. Rhee SG, Kang SW, Chang TS, Jeong W, and Kim K. Peroxiredoxin, a novel family of peroxidases. *IUBMB Life* 52: 35–41, 2001.
262. Rhee SG, Kang SW, Netto LE, Seo MS, and Stadtman ER. A family of novel peroxidases, peroxiredoxins. *Biofactors* 10: 207–209, 1999.
263. Rocic P and Lucchesi PA. NAD(P)H oxidases and TGF-beta-induced cardiac fibroblast differentiation: Nox-4 gets Smad. *Circ Res* 97: 850–852, 2005.
264. Rodningen OK, Borresen-Dale AL, Alsner J, Hastie T, and Overgaard J. Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. *Radiother Oncol* 86: 314–320, 2008.
265. Romanska HM, Polak JM, Coleman RA, James RS, Harmer DW, Allen JC, and Bishop AE. iNOS gene upregulation is

- associated with the early proliferative response of human lung fibroblasts to cytokine stimulation. *J Pathol* 197: 372–379, 2002.
266. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. *Cardiovasc Res* 63: 423–432, 2004.
 267. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature* 362: 801–809, 1993.
 268. Rotter JI, Vadheim CM, and Rimoin DL. Genetics of diabetes mellitus. In: Rifkin H, Porter D, editors, *Diabetes mellitus: theory and practice*. 4th ed. Amsterdam: Elsevier; 1990, pp 378–413.
 269. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G, and Smith MA. Redox-active iron mediates amyloid-beta toxicity. *Free Radic Biol Med* 30: 447–450, 2001.
 270. Roy S, Khanna S, Nallu K, Hunt TK, and Sen CK. Dermal wound healing is subject to redox control. *Mol Ther* 13: 211–220, 2006.
 271. Rubin H, Chow M, and Yao A. Cellular aging, destabilization, and cancer. *Proc Natl Acad Sci U S A* 93: 1825–1830, 1996.
 272. Sadoshima J, Aoki H, and Izumo S. Angiotensin II and serum differentially regulate expression of cyclins, activity of cyclin-dependent kinases, and phosphorylation of retinoblastoma gene product in neonatal cardiac myocytes. *Circ Res* 80: 228–241, 1997.
 273. Saeed M, Yang Y, Deng HX, Hung WY, Siddique N, Dellefave L, Gellera C, Andersen PM, and Siddique T. Age and founder effect of SOD1 A4V mutation causing ALS. *Neurology* 72: 1634–1639, 2009.
 274. Sakamaki T, Casimiro MC, Ju X, Quong AA, Katiyar S, Liu M, Jiao X, Li A, Zhang X, Lu Y, Wang C, Byers S, Nicholson R, Link T, Shemluck M, Yang J, Fricke ST, Novikoff PM, Papanikolaou A, Arnold A, Albanese C, and Pestell R. Cyclin D1 determines mitochondrial function in vivo. *Mol Cell Biol* 26: 5449–5469, 2006.
 275. Salonen JT, Nyyssonen K, Tuomainen TP, Maenpaa PH, Korpela H, Kaplan GA, Lynch J, Helmrich SP, and Salonen R. Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow up study in men. *Br Med J* 311: 1124–1127, 1995.
 276. Sarsour EH, Agarwal M, Pandita TK, Oberley LW, and Goswami PC. Manganese superoxide dismutase protects the proliferative capacity of confluent normal human fibroblasts. *J Biol Chem* 280: 18033–18041, 2005.
 277. Sarsour EH, Venkataraman S, Kalen AL, Oberley LW, and Goswami PC. Manganese superoxide dismutase activity regulates transitions between quiescent and proliferative growth. *Aging Cell* 7: 405–417, 2008.
 278. Sauer H, Wartenberg M, and Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. *Cell Physiol Biochem* 11: 173–186, 2001.
 279. Savitsky PA and Finkel T. Redox regulation of Cdc25C. *J Biol Chem* 277: 20535–20540, 2002.
 280. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, and Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. *J Neurochem* 74: 270–279, 2000.
 281. Scarabelli T, Stephanou A, Rayment N, Pasini E, Comini L, Curello S, Ferrarri R, Knight R, and Latchman D. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. *Circulation* 104: 253–256, 2001.
 282. Schafer FQ and Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. *Free Radic Biol Med* 30: 1191–1212, 2001.
 283. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompaker R, Kops GJ, Lam EW, Burgering BM, and Medema RH. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. *Mol Cell Biol* 22: 7842–7852, 2002.
 284. Schrader M and Fahimi HD. Mammalian peroxisomes and reactive oxygen species. *Histochem Cell Biol* 122: 383–393, 2004.
 285. Schriener SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, Emond M, Coskun PE, Ladiges W, Wolf N, Van Remmen H, Wallace DC, and Rabinovitch PS. Extension of murine life span by overexpression of catalase targeted to mitochondria. *Science* 308: 1909–1911, 2005.
 286. Schwartz SM, deBlois D, and O'Brien ER. The intima: soil for atherosclerosis and restenosis. *Circ Res* 77: 445–465, 1995.
 287. Sebastian B, Kakizuka A, and Hunter T. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. *Proc Natl Acad Sci U S A* 90: 3521–3524, 1993.
 288. Sekharam M, Trotti A, Cunnick JM, and Wu J. Suppression of fibroblast cell cycle progression in G₁ phase by N-acetylcysteine. *Toxicol Appl Pharmacol* 149: 210–216, 1998.
 289. Semsei I. On the nature of aging. *Mech Ageing Dev* 117: 93–108, 2000.
 290. Sen CK and Roy S. Redox signals in wound healing. *Biochim Biophys Acta* 1780: 1348–1361, 2008.
 291. Senel O, Cetinkale O, Ozbay G, Ahcioglu F, and Bulan R. Oxygen free radicals impair wound healing in ischemic rat skin. *Ann Plast Surg* 39: 516–523, 1997.
 292. Serafini M, Villano D, Spera G, and Pellegrini N. Redox molecules and cancer prevention: the importance of understanding the role of the antioxidant network. *Nutr Cancer* 56: 232–240, 2006.
 293. Serra V, von Zglinicki T, Lorenz M, and Saretzki G. Extracellular superoxide dismutase is a major antioxidant in human fibroblasts and slows telomere shortening. *J Biol Chem* 278: 6824–6830, 2003.
 294. Serrano M and Blasco MA. Putting the stress on senescence. *Curr Opin Cell Biol* 13: 748–753, 2001.
 295. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, and DePinto RA. Role of the INK4a locus in tumor suppression and cell mortality. *Cell* 85: 27–37, 1996.
 296. Shackelford RE, Kaufmann WK, and Paules RS. Cell cycle control, checkpoint mechanisms, and genotoxic stress. *Environ Health Perspect* 107(suppl 1): 5–24, 1999.
 297. Shafrir E. Development and consequences of insulin resistance: lessons from animals with hyperinsulinaemia. *Diabetes Metab* 22: 122–131, 1996.
 298. Sharma GG, Gupta A, Wang H, Scherthan H, Dhar S, Gandhi V, Iliakis G, Shay JW, Young CS, and Pandita TK. hTERT associates with human telomeres and enhances genomic stability and DNA repair. *Oncogene* 22: 131–146, 2003.
 299. Sherr CJ. Mammalian G₁ cyclins and cell cycle progression. *Proc Assoc Am Physicians* 107: 181–186, 1995.
 300. Sherr CJ and Roberts JM. Living with or without cyclins and cyclin-dependent kinases. *Genes Dev* 18: 2699–2711, 2004.
 301. Shin HS, Lee HJ, Nishida M, Lee MS, Tamura R, Yamashita S, Matsuzawa Y, Lee IK, and Koh GY. Betacellulin and amphiregulin induce upregulation of cyclin D1 and DNA synthesis activity through differential signaling pathways in vascular smooth muscle cells. *Circ Res* 93: 302–310, 2003.

302. Shukla A, Rasik AM, and Patnaik GK. Depletion of reduced glutathione, ascorbic acid, vitamin E and antioxidant defence enzymes in a healing cutaneous wound. *Free Radic Res* 26: 93–101, 1997.
303. Sicinska E, Aifantis I, Le Cam L, Swat W, Borowski C, Yu Q, Ferrando AA, Levin SD, Geng Y, von Boehmer H, and Sicinski P. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. *Cancer Cell* 4: 451–461, 2003.
304. Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, Robker RL, Richards JS, McGinnis LK, Biggers JD, Eppig JJ, Bronson RT, Elledge SJ, and Weinberg RA. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. *Nature* 384: 470–474, 1996.
305. Siddique T and Deng HX. Genetics of amyotrophic lateral sclerosis. *Hum Mol Genet* 5 Spec No: 1465–1470, 1996.
306. Simon HU, Haj-Yehia A, and Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. *Apoptosis* 5: 415–418, 2000.
307. Sinnaeve P, Varenne O, Collen D, and Janssens S. Gene therapy in the cardiovascular system: an update. *Cardiovasc Res* 44: 498–506, 1999.
308. Smith JR and Pereira-Smith OM. Replicative senescence: implications for in vivo aging and tumor suppression. *Science* 273: 63–67, 1996.
309. Smith TW and Lippa CF. Ki-67 immunoreactivity in Alzheimer's disease and other neurodegenerative disorders. *J Neuropathol Exp Neurol* 54: 297–303, 1995.
310. St Clair DK, Oberley TD, Muse KE, and St Clair WH. Expression of manganese superoxide dismutase promotes cellular differentiation. *Free Radic Biol Med* 16: 275–282, 1994.
311. Steiling H, Munz B, Werner S, and Brauchle M. Different types of ROS-scavenging enzymes are expressed during cutaneous wound repair. *Exp Cell Res* 247: 484–494, 1999.
312. Steinhubl SR. Why have antioxidants failed in clinical trials? *Am J Cardiol* 101: 14D–19D, 2008.
313. Stoll LL, McCormick ML, Denning GM, and Weintraub NL. Antioxidant effects of statins. *Timely Top Med Cardiovasc Dis* 9: E1, 2005.
314. Sullivan SG, Chiu DT, Errasfa M, Wang JM, Qi JS, and Stern A. Effects of H₂O₂ on protein tyrosine phosphatase activity in HER14 cells. *Free Radic Biol Med* 16: 399–403, 1994.
315. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, and Finkel T. Requirement for generation of H₂O₂ for platelet-derived growth factor signal transduction. *Science* 270: 296–299, 1995.
316. Swenne I. Effects of aging on the regenerative capacity of the pancreatic B-cell of the rat. *Diabetes* 32: 14–19, 1983.
317. Sylvester AM, Chen D, Krasinski K, and Andres V. Role of c-fos and E2F in the induction of cyclin A transcription and vascular smooth muscle cell proliferation. *J Clin Invest* 101: 940–948, 1998.
318. Temin HM. Stimulation by serum of multiplication of stationary chicken cells. *J Cell Physiol* 78: 161–170, 1971.
319. Thannickal VJ and Fanburg BL. Activation of an H₂O₂-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1. *J Biol Chem* 270: 30334–30338, 1995.
320. Tonks NK. Redox redux: revisiting PTPs and the control of cell signaling. *Cell* 121: 667–670, 2005.
321. Tothova Z and Gilliland DG. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. *Cell Stem Cell* 1: 140–152, 2007.
322. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C, Armstrong SA, Passegue E, DePinho RA, and Gilliland DG. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. *Cell* 128: 325–339, 2007.
323. Toyoshima H and Hunter T. p27, a novel inhibitor of G₁ cyclin-Cdk protein kinase activity, is related to p21. *Cell* 78: 67–74, 1994.
324. Traister A, Abashidze S, Gold V, Plachta N, Karchovsky E, Patel K, and Weil M. Evidence that nitric oxide regulates cell-cycle progression in the developing chick neuroepithelium. *Dev Dyn* 225: 271–276, 2002.
325. Tsan MF. Superoxide dismutase and pulmonary oxygen toxicity: lessons from transgenic and knockout mice [Review]. *Int J Mol Med* 7: 13–19, 2001.
326. Tsan MF, White JE, Caska B, Epstein CJ, and Lee CY. Susceptibility of heterozygous MnSOD gene-knockout mice to oxygen toxicity. *Am J Respir Cell Mol Biol* 19: 114–120, 1998.
327. Tschien SI, Dhawan S, Gurlo T, and Bhushan A. Age-dependent decline in beta cell proliferation restricts the capacity of beta cell regeneration in mice. *Diabetes* 58: 1312–1320, 2009.
328. Tu BP, Kudlicki A, Rowicka M, and McKnight SL. Logic of the yeast metabolic cycle: temporal compartmentalization of cellular processes. *Science* 310: 1152–1158, 2005.
329. Uchida T, Nakamura T, Hashimoto N, Matsuda T, Kotani K, Sakaue H, Kido Y, Hayashi Y, Nakayama KI, White MF, and Kasuga M. Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice. *Nat Med* 11: 175–182, 2005.
330. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, and Telser J. Free radicals and antioxidants in normal physiological functions and human disease. *Int J Biochem Cell Biol* 39: 44–84, 2007.
331. Van Remmen H, Ikeno Y, Hamilton M, Pahlavani M, Wolf N, Thorpe SR, Alderson NL, Baynes JW, Epstein CJ, Huang TT, Nelson J, Strong R, and Richardson A. Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. *Physiol Genomics* 16: 29–37, 2003.
332. Vande Berg JS, Rose MA, Payne WG, Haywood-Reid PL, and Robson MC. Significance of cell cycle for wound stratification in clinical trials: analysis of a pressure ulcer clinical trial utilizing cyclin D/cdk4. *Wound Repair Regen* 11: 11–18, 2003.
333. Vincent I, Jicha G, Rosado M, and Dickson DW. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. *J Neurosci* 17: 3588–3598, 1997.
334. von Wangenheim KH and Peterson HP. Control of cell proliferation by progress in differentiation: clues to mechanisms of aging, cancer causation and therapy. *J Theoret Biol* 193: 663–678, 1998.
335. Vozenin-Brotans MC, Sivan V, Gault N, Renard C, Gefrotin C, Delanian S, Lefaix JL, and Martin M. Antifibrotic action of Cu/Zn SOD is mediated by TGF-beta1 repression and phenotypic reversion of myofibroblasts. *Free Radic Biol Med* 30: 30–42, 2001.
336. Wallace K, Burt AD, and Wright MC. Liver fibrosis. *Biochem J* 411: 1–18, 2008.
337. Walters DM, Cho HY, and Kleeberger SR. Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: a potential role for Nrf2. *Antioxid Redox Signal* 10: 321–332, 2008.

338. Wang C, Li Z, Lu Y, Du R, Katiyar S, Yang J, Fu M, Leader JE, Quong A, Novikoff PM, and Pestell RG. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. *Proc Natl Acad Sci U S A* 103: 11567–11572, 2006.
339. Wang F, Nguyen M, Qin FX, and Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. *Aging Cell* 6: 505–514, 2007.
340. Wang W, Furneaux H, Cheng H, Caldwell MC, Hutter D, Liu Y, Holbrook N, and Gorospe M. HuR regulates p21 mRNA stabilization by UV light. *Mol Cell Biol* 20: 760–769, 2000.
341. Wartenberg M, Diedershausen H, Hescheler J, and Sauer H. Growth stimulation versus induction of cell quiescence by hydrogen peroxide in prostate tumor spheroids is encoded by the duration of the Ca(2+) response. *J Biol Chem* 274: 27759–27767, 1999.
342. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, Bohm M, and Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. *Mol Pharmacol* 59: 646–654, 2001.
343. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, and Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. *Arterioscler Thromb Vasc Biol* 22: 300–305, 2002.
344. Waypa GB, Marks JD, Mack MM, Boriboun C, Mungai PT, and Schumacker PT. Mitochondrial reactive oxygen species trigger calcium increases during hypoxia in pulmonary arterial myocytes. *Circ Res* 91: 719–726, 2002.
345. Wei GL, Krasinski K, Kearney M, Isner JM, Walsh K, and Andres V. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. *Circ Res* 80: 418–426, 1997.
346. Weydert C, Roling B, Liu J, Hinkhouse MM, Ritchie JM, Oberley LW, and Cullen JJ. Suppression of the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese superoxide dismutase. *Mol Cancer Ther* 2: 361–369, 2003.
347. Weydert CJ, Waugh TA, Ritchie JM, Iyer KS, Smith JL, Li L, Spitz DR, and Oberley LW. Overexpression of manganese or copper-zinc superoxide dismutase inhibits breast cancer growth. *Free Radic Biol Med* 41: 226–237, 2006.
348. Wright WE and Shay JW. Cellular senescence as a tumor-protection mechanism: the essential role of counting. *Curr Opin Genet Dev* 11: 98–103, 2001.
349. Wright WE and Shay JW. Historical claims and current interpretations of replicative aging. *Nat Biotechnol* 20: 682–688, 2002.
350. Yamamoto K, Volkl A, Hashimoto T, and Fahimi HD. Catalase in guinea pig hepatocytes is localized in cytoplasm, nuclear matrix and peroxisomes. *Eur J Cell Biol* 46: 129–135, 1988.
351. Yamauchi A and Bloom ET. Control of cell cycle progression in human natural killer cells through redox regulation of expression and phosphorylation of retinoblastoma gene product protein. *Blood* 89: 4092–4099, 1997.
352. Yan Y, Frisen J, Lee MH, Massague J, and Barbacid M. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. *Genes Dev* 11: 973–983, 1997.
353. Yant LJ, Ran Q, Rao L, Van Remmen H, Shibata T, Belter JG, Motta L, Richardson A, and Prolla TA. The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. *Free Radic Biol Med* 34: 496–502, 2003.
354. Yellon DM and Hausenloy DJ. Myocardial reperfusion injury. *N Engl J Med* 357: 1121–1135, 2007.
355. Zangar RC, Davydov DR, and Verma S. Mechanisms that regulate production of reactive oxygen species by cytochrome P450. *Toxicol Appl Pharmacol* 199: 316–331, 2004.
356. Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, and Elledge SJ. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. *Nature* 387: 151–158, 1997.
357. Zhang Y, Zhao W, Zhang HJ, Domann FE, and Oberley LW. Overexpression of copper zinc superoxide dismutase suppresses human glioma cell growth. *Cancer Res* 62: 1205–1212, 2002.
358. Zhao W, Zhao T, Chen Y, Ahokas RA, and Sun Y. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. *Mol Cell Biochem* 317: 43–50, 2008.
359. Zhu X, Di Y, Hu C, and Wang Z. Expression of positive and negative regulators of cell cycle during wound healing. *Chin Med J (Engl)* 115: 326–330, 2002.
360. Zhu X, Hu C, Zhang Y, Li L, and Wang Z. Expression of cyclin-dependent kinase inhibitors, p21cip1 and p27kip1, during wound healing in rats. *Wound Repair Regen* 9: 205–212, 2001.
361. Zhu X, Raina AK, Perry G, and Smith MA. Alzheimer's disease: the two-hit hypothesis. *Lancet Neurol* 3: 219–226, 2004.
362. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, and Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. *J Neuropathol Exp Neurol* 59: 880–888, 2000.
363. Zhu X, Siedlak SL, Wang Y, Perry G, Castellani RJ, Cohen ML, and Smith MA. Neuronal binucleation in Alzheimer disease hippocampus. *Neuropathol Appl Neurobiol* 34: 457–465, 2008.
364. Zieske JD. Expression of cyclin-dependent kinase inhibitors during corneal wound repair. *Prog Retin Eye Res* 19: 257–270, 2000.
365. Zou MH, Shi C, and Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. *J Clin Invest* 109: 817–826, 2002.
366. Zweier JL. Measurement of superoxide-derived free radicals in the reperfused heart: evidence for a free radical mechanism of reperfusion injury. *J Biol Chem* 263: 1353–1357, 1988.

Address correspondence to:

Prabhat C. Goswami, Ph.D.
 Free Radical & Radiation Biology Program
 B180 Medical Laboratories
 Department of Radiation Oncology
 The University of Iowa
 500 Hawkins Drive
 Iowa City, IA 52242-1181

E-mail: prabhat-goswami@uiowa.edu

Date of first submission at ARS Central, February 18, 2009; date of final revised submission, June 4, 2009; date of acceptance, June 5, 2009.

Abbreviations Used

ALS = amyotrophic lateral sclerosis
 Ang II = angiotensin II
 AP-1 = activator protein 1
 ARE = antioxidant response element
 CAT = catalase
 CDK = cyclin-dependent kinase
 CKI = cyclin-dependent kinase inhibitor
 COPD = chronic obstructive pulmonary disease
 CuZnSOD = copper zinc superoxide dismutase
 Cys = cysteine
 CySS = cystine
 DCFH₂-DA = 2',7'-dichlorodihydrofluorescein diacetate
 DHE = dihydroethidine
 ECM = Extracellular matrix
 EcSOD = extracellular superoxide dismutase
 ERK = extracellular signal-regulated kinase
 ETC = electron-transport chain
 FFA = free fatty acid
 FoxO = Forkhead transcription factor
 GPx = glutathione peroxidase
 Grx = glutaredoxin
 GSH = glutathione
 GSK = glycogen synthase kinase
 GSSG = glutathione disulfide
 HIF-1 = hypoxia-inducible factor 1
 HSC = hematopoietic stem cell
 HSC = hepatic stellate cells
 IGF-1 = insulin-like growth factor 1
 iNOS = inducible nitric oxide synthase
 IPF = idiopathic pulmonary fibrosis
 MAPK = mitogen-activated protein kinase
 MnSOD = manganese superoxide dismutase
 MnTBAP = manganese (III) tetrakis
 (4-benzoic acid) porphyrin
 NAC = N-acetyl-L-cysteine
 NADPH = nicotinamide adenine dinucleotide phosphate
 NO = nitric oxide
 NOS = nitric oxide synthase
 NOX = NADPH oxidase
 NRF1 = nuclear respiratory factor 1
 PCNA = proliferating cell nuclear antigen
 PDGF = platelet-derived growth factor
 PI3K = phosphatidylinositol-3-kinase
 PIP = phosphatidylinositol phosphate
 Prx = peroxiredoxin
 PTEN = phosphatase and tensin homologue
 Rb = retinoblastoma
 Redox = reduction and oxidation
 Ref-1 = redox factor 1
 RIF = radiation-induced fibrosis
 RNS = reactive nitrogen species
 ROS = reactive oxygen species
 TGF- β = transforming growth factor-beta
 VSMC = vascular smooth muscle cell
 YMC = yeast metabolic cycle

